

1                                   **Controlled human malaria infection with PvW1 – a new clone of**  
2                                   ***Plasmodium vivax* with high quality genome assembly**

3  
4 Angela M. Minassian<sup>1\*</sup>, Yrene Themistocleous<sup>1†</sup>, Sarah E. Silk<sup>1,2</sup>, Jordan R. Barrett<sup>1,2</sup>, Alison Kemp<sup>3,4</sup>,  
5 Doris Quinkert<sup>1,2</sup>, Carolyn M. Nielsen<sup>1,2</sup>, Nick J. Edwards<sup>1</sup>, Thomas A. Rawlinson<sup>1</sup>, Fernando Ramos  
6 Lopez<sup>1</sup>, Wanlapa Roobsoong<sup>5</sup>, Katherine J. Ellis<sup>1</sup>, Jee-Sun Cho<sup>1</sup>, Eerik Aunin<sup>3</sup>, Thomas D. Otto<sup>3</sup>, Adam J.  
7 Reid<sup>3</sup>, Florian Bach<sup>6</sup>, Geneviève M. Labbé<sup>1</sup>, Ian D. Poulton<sup>1</sup>, Arianna Marini<sup>1</sup>, Marija Zarić<sup>1</sup>, Margaux  
8 Mulatier<sup>1</sup>, Raquel Lopez Ramon<sup>1</sup>, Megan Baker<sup>1</sup>, Celia H. Mitton<sup>1</sup>, Jason C. Sousa<sup>7</sup>, Nattawan  
9 Rachaphaew<sup>5</sup>, Chalermpon Kumpitak<sup>5</sup>, Nongnuj Maneechai<sup>5</sup>, Chayanut Suansomjit<sup>5</sup>, Tianrat Piteekan<sup>8</sup>,  
10 Mimi M. Hou<sup>1</sup>, Baktash Khozoe<sup>1</sup>, David J. Roberts<sup>9</sup>, Alison M. Lawrie<sup>1</sup>, Andrew M. Blagborough<sup>10</sup>, Fay L.  
11 Nugent<sup>1</sup>, Iona J. Taylor<sup>1</sup>, Kimberly J. Johnson<sup>1</sup>, Philip J. Spence<sup>6</sup>, Jetsumon Sattabongkot<sup>5</sup>, Sumi Biswas<sup>1</sup>,  
12 Julian C. Rayner<sup>3,4</sup>, and Simon J. Draper<sup>1,2\*</sup>.

13

14 <sup>1</sup> The Jenner Institute, University of Oxford, Oxford, UK.

15 <sup>2</sup> Department of Biochemistry, University of Oxford, Oxford, UK.

16 <sup>3</sup> Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK.

17 <sup>4</sup> Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK.

18 <sup>5</sup> Mahidol Vivax Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400,  
19 Thailand.

20 <sup>6</sup> Institute of Immunology and Infection Research, University of Edinburgh, Edinburgh, UK.

21 <sup>7</sup> Walter Reed Army Institute of Research, 503 Robert Grant Avenue, Silver Spring, MD 20910, USA.

22 <sup>8</sup> Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University,  
23 Bangkok 10400, Thailand.

24 <sup>9</sup> Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of  
25 Oxford, Oxford, UK.

26 <sup>10</sup> Department of Pathology, University of Cambridge, Cambridge, UK.

27

28 <sup>†</sup> These authors contributed equally.

29 <sup>\*</sup> Corresponding authors: AMM ([angela.minassian@ndm.ox.ac.uk](mailto:angela.minassian@ndm.ox.ac.uk)); SJD ([simon.draper@bioch.ox.ac.uk](mailto:simon.draper@bioch.ox.ac.uk))

30 **Abstract**

31 Controlled human malaria infection (CHMI) provides a highly informative means to investigate host-  
32 pathogen interactions and enable *in vivo* proof-of-concept efficacy testing of new drugs and vaccines.  
33 However, unlike *Plasmodium falciparum*, well-characterized *P. vivax* parasites that are safe and suitable  
34 for use in modern CHMI models are limited. Here, two healthy malaria-naïve UK adults with universal  
35 donor blood group were safely infected with a clone of *P. vivax* from Thailand by mosquito-bite CHMI.  
36 Parasitemia developed in both volunteers and, prior to treatment, each volunteer donated blood to  
37 produce a cryopreserved stabilate of infected red blood cells. Following stringent safety screening, the  
38 parasite stabilate from one of these donors (“PvW1”) was thawed and used to inoculate six healthy  
39 malaria-naïve UK adults by blood-stage CHMI, at three different dilutions. Parasitemia developed in all  
40 volunteers, who were then successfully drug treated. PvW1 parasite DNA was isolated and sequenced to  
41 produce a high quality genome assembly by using a hybrid assembly method. We analysed leading  
42 vaccine candidate antigens and multigene families, including the Vivax interspersed repeat (VIR) genes  
43 of which we identified 1145 in the PvW1 genome. Our genomic analysis will guide future assessment of  
44 candidate vaccines and drugs, as well as experimental medicine studies.

45

## 46 **Introduction**

47 The majority of human malaria is caused by two species of parasite – *Plasmodium falciparum* and *P.*  
48 *vivax*. Infection is initiated by an infected *Anopheles* mosquito bite, delivering sporozoites which rapidly  
49 migrate to and infect the liver. Asexual replication in the liver sees each infected cell produce thousands  
50 of merozoites. These rupture out into the blood and infect red blood cells (RBC), before undergoing  
51 exponential growth that leads to clinical symptoms and the associated morbidity and mortality. *P. vivax*  
52 is the predominant cause of malaria outside of Africa and is more geographically widespread than *P.*  
53 *falciparum*, with 2.5 billion people living at risk in Latin America, Oceania, Asia and the horn of Africa (1).  
54 Moreover, recent data demonstrate a significant burden of morbidity and associated mortality in young  
55 children and pregnant women (2), challenging the long-held dogma that this parasite is “benign” (3).

56 A number of factors also underlie the differing epidemiology of *P. vivax* and make it more difficult to  
57 control and eliminate than *P. falciparum* (4). Most notably earlier development of gametocytes leads to  
58 transmission prior to symptom onset, and its ability to form dormant liver-stage forms, termed  
59 “hypnozoites”, causes waves of relapsing blood-stage parasitemia and sustained transmission (5).  
60 However, despite a clear global health need to develop an effective vaccine and improved antimalarial  
61 drugs, these efforts continue to lag behind those for *P. falciparum*. The reasons for this are numerous,  
62 but perhaps most significant is the fact that *P. vivax* has not been able to be adapted to long-term *in*  
63 *vitro* culture, despite extensive efforts. This has severely limited laboratory studies, as well as the  
64 development of modern controlled human malaria infection (CHMI) models, which rely on a well-  
65 defined isolate of *P. vivax*, and would enable *in vivo* efficacy testing of candidate vaccines and anti-  
66 malarial drugs in proof-of-concept clinical trials. This is in contrast to *P. falciparum* where *in vitro* culture  
67 and sophisticated genetic modification experiments are carried out all over the world, and CHMI can be  
68 initiated by the traditional mosquito-bite method, or by injection of cryopreserved sporozoites or an  
69 inoculum of blood-stage parasites (6). Most of these studies have been carried out in non-endemic  
70 settings, but CHMI trial capacity is now expanding across endemic countries in Africa, enabled by the use  
71 of cryopreserved sporozoites. In contrast, modern CHMI with *P. vivax* has been less utilized, with only a  
72 handful of studies reported (7).

73 For mosquito-bite *P. vivax* CHMI trials, most have taken place in Cali, Columbia (8-11) plus one at the  
74 Walter Reed Army Institute of Research (WRAIR), USA (12), with 108 volunteers challenged in total. Such  
75 trials necessitate production of infected mosquitoes in an endemic setting using fresh gametocytes from  
76 an infected patient. Shipment of the mosquitoes to non-endemic areas, and timing these activities with

77 recruitment of volunteers who may receive an intervention such as a vaccine, poses significant logistical  
78 challenges. Moreover, a different isolate of *P. vivax* is inevitably used for every trial which can hamper  
79 interpretation of the results and inter-study comparability. These studies also pose the risk of relapse,  
80 and thus require participants to be screened for glucose-6-phosphate dehydrogenase (G6PD) deficiency  
81 (to avoid hemolysis induced by primaquine treatment). They also require assessment of the volunteers'  
82 ability to metabolize primaquine, given relapsing infection occurred in two volunteers in the CHMI study  
83 at WRAIR despite primaquine treatment. Here, drug failure was subsequently linked to the volunteers'  
84 cytochrome P450 2D6 (CYP2D6) genotypes that were predicted to be poor or intermediate metabolizer  
85 phenotypes of the drug (13).

86 The use of the blood-stage CHMI model (14, 15) has several advantages over mosquito-bite CHMI,  
87 although does not mimic the route of natural infection. Here a cryopreserved stabilate of infected RBC  
88 (iRBC) is produced from a donor volunteer, enabling subsequent direct blood-stage inoculation of other  
89 volunteers with small numbers of parasites. This model is more practical in non-endemic settings;  
90 enables access to the parasite's genetic data before CHMI; removes all risk of relapsing infection; and  
91 enables multiple studies with the same strain of parasite (for which a safety database can be  
92 established). In the case of *P. falciparum*, this model has also proved particularly suitable for estimating  
93 the blood-stage parasite multiplication rate (PMR) (16) and for enabling experimental transmission to  
94 mosquitoes (17), as compared to studies initiated by mosquito-bite. The blood-stage model is also  
95 advantageous because it extends the period of blood-stage infection, allowing for longer studies of the  
96 human immune response and also switching/selection of parasite variant surface antigens (18).

97 Two cryopreserved stabilates of blood-stage *P. vivax* have been reported to-date, both produced by the  
98 group at the QIMR Berghofer Medical Research Institute, Australia and obtained from returning  
99 travellers who donated infected blood prior to treatment. The first isolate, HMPBS-*Pv* from the Solomon  
100 Islands, was safely tested by blood-stage CHMI in eight volunteers (19, 20), however this necessitated  
101 recruitment of individuals with blood group A to match that of the donor. The second *P. vivax* isolate,  
102 HMP013-*Pv*, was from India and a blood group O+ donor. This has been tested in healthy adult  
103 volunteers and showed successful induction of gametocytemia and experimental transmission of *P.*  
104 *vivax* from humans to mosquitoes (21), and also enabled trials of candidate drugs and further  
105 methodology development (22, 23).

106 Here we take a significant step forward for *P. vivax* CHMI by establishing a well-characterized Thai clone  
107 of *P. vivax* suitable for both mosquito-bite and blood-stage CHMI. We elected to produce a

108 cryopreserved stabilate of iRBC from blood donated by healthy volunteers infected via mosquito-bite  
109 CHMI, as opposed to using a blood donation from a returning traveller. This provided numerous  
110 advantages in terms of logistical timing, and our ability to recruit in advance volunteers who passed a  
111 full health screen and who had universal donor blood group. In real-time we were able to select  
112 mosquitoes infected in Thailand with a single *P. vivax* genotype, thus avoiding production of a  
113 cryopreserved iRBC stabilate from a polyclonal infection. It also minimized the time from mosquito to  
114 blood bank (compared to infected returning travellers); this is important as it has previously been shown  
115 that mosquitoes reset parasite virulence and expression of variant surface antigens (24). Following  
116 production of the cryopreserved parasite stabilate, which we called “PvW1”, we demonstrated safety  
117 and infectivity by blood-stage CHMI in six healthy adults, and we also report a full genomic analysis of  
118 the new PvW1 clone.

119 **Results**

120 **Source patient case-finding and preparation of infected mosquitoes**

121 For infection of mosquitoes, source patients were recruited from a medical clinic in southern Thailand.  
122 Patient blood samples that tested positive for *P. vivax* and negative for filarial disease were fed to  
123 *Anopheles dirus* mosquitoes via a direct membrane feeding system in Thailand. Oocyst and sporozoite  
124 counts subsequently confirmed successful production of three independent batches of infected  
125 mosquitoes (**Fig. S1A**). In parallel, and in real-time, source patient samples underwent additional and  
126 rigorous testing in the UK for blood-borne infections and mosquito-borne diseases other than malaria;  
127 all tests were negative. Nested PCR reported mono-infection with *P. vivax* (**Fig. S1B,C**), thus confirming  
128 the diagnosis in Thailand, however, genotyping analysis suggested that only one blood sample (C05-001)  
129 contained a single *P. vivax* genotype (**Fig. S1A**). Mosquitoes fed off this patient's blood were therefore  
130 selected and shipped from Thailand to the UK.

131

132 **Screening of healthy UK volunteers for blood donation**

133 In parallel we enrolled two healthy UK adult volunteers into the VAC068 clinical trial (**Fig. S2**). These  
134 volunteers were specifically screened to be universal blood donors (blood group O rhesus-negative),  
135 Duffy-blood group positive (7, 25); G6PD normal (26); and to have a CYP2D6 genotype predicted to be  
136 an extensive metabolizer phenotype (27) alongside satisfactory demonstration of primaquine  
137 metabolism following administration of a single test dose of drug (13) (**Table S1, Fig. S3**). Each volunteer  
138 also underwent an extensive screen for blood-borne infections; all test results were negative, except  
139 both participants were IgG seropositive for Epstein-Barr virus (EBV) and cytomegalovirus (CMV) (**Table**  
140 **S1**), indicating past infection. However, we did not exclude volunteers based on their serostatus for  
141 these two viruses.

142

143 **Mosquito-bite CHMI – safety and parasite growth dynamics**

144 For the C05-001 mosquito batch, the mean [range] number of oocysts per mosquito was 3 [0-6] at day 7  
145 post-feeding and the median score for number of sporozoites observed in the salivary glands at day 14  
146 post-feeding was +2 (defined as >10-100 sporozoites) (**Fig. S1A**). This was relatively low but agreed to be  
147 sufficient for human transmission. Subsequently, the two healthy UK adult volunteers screened and  
148 consented to take part in VAC068 were each exposed to five “infectious bites” as defined post-skin

149 feeding by microscopic examination of each mosquito. To achieve this, volunteers 01-004 and 01-008  
150 required 17 and 33 mosquitoes, respectively, to bite their arm.

151 Parasites were first reliably detected in the blood of both volunteers by qPCR at the evening clinic visit 8  
152 days post-CHMI (dC+8.5), and parasitemia then steadily rose over time (**Fig. 1A, Table S2**). Over the  
153 course of the CHMI period, the two volunteers experienced a range of solicited adverse events (AEs),  
154 with both reporting grade 3 fatigue and at least grade 2 anorexia, chills, feverishness, headache,  
155 malaise, nausea and sweats (**Fig. 1B**). Both volunteers were admitted for blood donation when they met  
156 protocol-specified criteria defined by symptoms and or threshold levels of parasitemia as measured in  
157 genome copies (gc)/mL by qPCR. This occurred on the morning of dC+14 for both volunteers, who both  
158 crossed the 10,000 gc/mL threshold on dC+13.5 and developed fever on dC+14. Following admission to  
159 the clinical trials unit, a 250 mL blood sample was collected (at dC+14 for volunteer 01-008 and dC+14.5  
160 for volunteer 01-004); both were positive by thick film microscopy and reported 16,717 or 31,010 gc/mL  
161 by qPCR, respectively. Prior to cryopreservation, these blood samples were then randomized and  
162 relabelled either “Donor 1” or “Donor 2” and are now referred to as such in the Results.

163 After blood donation, each volunteer was immediately treated with Riamet® followed by a 14-day  
164 course of primaquine; no supportive treatment or hospital admission was required for either volunteer.  
165 Monitoring by qPCR on days 1, 2, 4, 10 and 16 post-treatment showed a rapid decline in blood-stage  
166 parasitemia followed by negative readings for both volunteers (**Fig. 1A, Table S2**). Most solicited  
167 symptoms increased in severity in the first 24 hours after starting anti-malarial treatment (**Fig. S4A**).  
168 Objective fever also increased in the 24 hours post-treatment (**Fig. 1C**), and one volunteer developed a  
169 grade 3 pyrexia (**Fig. S4B**), but all symptoms had completely resolved within 5 days of starting  
170 treatment. Both volunteers also experienced some short-lived grade 1 or 2 AEs possibly related to the  
171 anti-malarial treatment (dizziness, insomnia and abdominal pain) (**Fig. S4C**). Very few unsolicited AEs (at  
172 least possibly related to CHMI) were reported by either volunteer (**Table S3A**), and only one grade 3  
173 unsolicited AE (migraine, not related to CHMI) was reported by 01-004 more than 2 months post-  
174 challenge, requiring attendance to their doctor and resolving within 48 hours (**Table S3B**). Lymphocyte  
175 and platelet counts dropped in both volunteers around the time of blood donation (platelets remained  
176 within the normal range but both developed a grade 2 lymphocytopenia), rising back to pre-challenge  
177 levels within 48 hours (**Fig. 1D-E and Table S3C**). Volunteer 01-008 also developed a transient grade 1  
178 anemia ~6 weeks post-challenge (123 g/L at dC+47) which may or may not have been related to CHMI,  
179 but this resolved within 3 months (131 g/L at dC+94).

180 Following completion of the study, the parasite multiplication rate (PMR) for both volunteers was  
181 calculated using a linear model fitted to log<sub>10</sub>-transformed qPCR data (28). These data showed  
182 comparable PMRs in both volunteers, with 10.7- and 11.5-fold growth per 48 hours (**Fig. 1G**). We also  
183 analysed gametocytemia using a qRT-PCR assay to detect mature female gametocyte *pvs25* transcripts.  
184 Volunteer 01-004 showed only low levels at the final time-point pre-treatment (dC+14.5) whilst none  
185 were detected in volunteer 01-008 (**Fig. 1H**).

186 Finally, with regard to longer-term safety monitoring, clinic visits at dC+45 and dC+90 gave rise to no  
187 safety concerns or indication of relapsing infection, and repeat serological tests for blood-borne  
188 infections at dC+90 all remained negative. Ongoing annual follow-up by email will continue for 5 years  
189 post-CHMI, however, as of time of writing (3 years post-primaquine treatment) no relapse of *P. vivax*  
190 has been diagnosed for either volunteer (see **Supplementary Text**).

191

#### 192 **Cryopreservation and *in vitro* testing of *P. vivax* infected blood**

193 After blood donation, the leukodepleted blood from both volunteers in VAC068 was processed, and the  
194 RBC mixed with Glycerolyte 57 to form a stabilate prior to cryopreservation. In total, 190 vials were  
195 frozen for Donor 1 and 185 for Donor 2. In process testing by qPCR indicated minimal or no loss of  
196 parasites during filtration (95% and 105% recovery for Donor 1 and Donor 2, respectively). We next  
197 tested for parasite viability in both cryopreserved stabilates. Vials were thawed and cells used in a short-  
198 term *in vitro* parasite culture assay, given *P. vivax* cannot currently be cultured long-term *in vitro*.  
199 Parasite growth was detectable by qPCR and light microscopy through one initial growth cycle in  
200 samples collected from Donor 1, with normal progression of parasite morphology seen on Giemsa  
201 stained thick and thin blood films (**Fig. 2**). However, no growth was discernible in samples obtained from  
202 Donor 2. We therefore undertook further QC testing on vials from Donor 1, with the material tested for  
203 sterility, mycoplasma and endotoxin; all tests were passed. Another screen for blood-borne infections  
204 was also conducted on the plasma derived directly from the blood donation; all tests were negative.

205

206 Finally, we also screened Donor 1 for the Kell blood group antigen because women of childbearing  
207 potential that receive a blood transfusion have a small additional risk of developing RBC alloantibodies  
208 that could cause problems during pregnancy. In particular, there is a potential risk of development of  
209 hemolytic disease of the newborn in relation to Kell antigen incompatibility, i.e. if Kell-positive donor



210 blood is transfused to a Kell-negative female recipient. However, testing of the donor's blood sample  
211 confirmed Kell antigen negativity, thereby allowing future universal administration of the cryopreserved  
212 *P. vivax* iRBC stabilate with respect to gender.

213

#### 214 **Blood-stage CHMI – PvW1 infectivity, parasite growth dynamics and safety**

215 Given all safety and viability tests were passed for the cryopreserved stabilate of *P. vivax* iRBC from  
216 Donor 1, we named this clonal isolate “PvW1” and proceeded to test safety and infectivity by blood-  
217 stage CHMI. We therefore recruited six healthy, malaria-naïve UK adults into the VAC069A clinical trial,  
218 comprising three groups of two volunteers (**Fig. S5**), and tested feasibility of infection at three different  
219 doses of PvW1 blood-stage inoculum. Five vials of the PvW1 cryopreserved stabilate were thawed and  
220 then combined to produce a single batch of blood-stage inoculum. Two volunteers receive a whole vial's  
221 worth of iRBC (“neat”), two volunteers received one fifth of the challenge dose via a 1:5 dilution, and  
222 the final two volunteers were inoculated with one twentieth of the dose via a 1:20 dilution. All six  
223 volunteers underwent blood-stage CHMI at the same time.

224 Blood-stage parasitemia was monitored as previously by qPCR, beginning one day after challenge (dC+1)  
225 (**Fig. 3A, Table S4**). All six volunteers were successfully infected, with a median time to diagnosis of  
226 15.25 days post-CHMI (range 12.5-16.5) (**Fig. 3B**). The median (range) parasitemia at diagnosis across all  
227 six volunteers was 9,178 (3,779 – 17,795) gc/mL (**Fig. 3C**). We also calculated the PMR as before using a  
228 linear model fitted to log<sub>10</sub>-transformed qPCR data (28). These data showed a median (range) of 5.7 (3.6  
229 – 7.0)-fold growth per 48 hours across the six volunteers (**Fig. 3D**), notably lower than that previously  
230 observed in the mosquito-bite CHMI study (**Fig. 1F**). There was also no discernible difference in the  
231 PMRs across the three different challenge dose cohorts (**Fig. 3D**); or across the three different Duffy  
232 blood group sero-phenotypes, all with median values between 5.3 – 5.9-fold growth per 48 hours (**Fig.**  
233 **3E**). We also analysed gametocytemia at the six time-points preceding diagnosis for each volunteer, and  
234 observed rising levels in all individuals (**Fig. 3F**). This was in clear contrast to the observations post-  
235 mosquito bite CHMI (**Fig. 1G**) and despite comparable (if not slightly lower) levels of overall blood-stage  
236 parasitemia as measured in gc/mL. Here, we also saw a strong positive correlation between the  
237 measured overall levels of parasitemia in gc/mL versus *pvs25* transcripts/ $\mu$ L (**Fig. 3G**).

238 With regards to safety, there were no serious adverse events (SAEs) in the VAC069A study and all  
239 volunteers completed treatment without complication. One volunteer withdrew at dC+28, with the

240 remaining five completing clinical follow-up at dC+90 (**Fig. S5**). The maximum severity of solicited AEs at  
241 any time during the CHMI period is shown for all six volunteers in **Fig. 4A**, with four volunteers reporting  
242 grade 3 solicited AEs (most commonly feverishness) persisting for 24 hours and one for 48 hours (**Table**  
243 **S5A**). The proportion of volunteers reporting solicited AEs specifically pre-diagnosis, peri-diagnosis and  
244 post-treatment is shown in **Fig. 4B**. Around the time of diagnosis, 33-50% of the volunteers reported  
245 mild-to-moderate symptoms; mainly fatigue, headache, myalgia, malaise, feverishness and chills.  
246 Symptoms peaked in severity in the first 24 hours after starting anti-malarial treatment with Riamet® or  
247 Malarone, with only one volunteer remaining asymptomatic (**Fig. 4B**). Objective fever also increased in  
248 the 24 hours post-treatment, with 3/6 volunteers developing pyrexia, one of each grades 1-3 (**Fig. 4C**,  
249 **Fig. S6A**). Nevertheless, most symptoms had completely resolved within a few days of starting  
250 treatment and only one volunteer still had headache and fatigue at 6 days post-starting treatment (T+6)  
251 (**Fig. 4B**). Three volunteers (50%) also experienced short-lived AEs possibly related to the anti-malarial  
252 drugs (50% moderate dizziness, 33% mild insomnia, cough and palpitations) (**Fig. S6B**). Very few  
253 unsolicited AEs (at least possibly related to CHMI) were reported by any of the volunteers (**Table S5B**).  
254 With regard to laboratory AEs (**Table S5C**), lymphocyte counts dropped significantly in 4/6 volunteers  
255 around the time of diagnosis or 1 day post-treatment (grade 3 lymphocytopenia in two volunteers), but  
256 all counts normalized within 6 days of starting treatment (**Fig. 4D**). Two volunteers developed a short-  
257 lived grade 2 thrombocytopenia, again normalizing within 6 days of treatment (**Fig. 4E**); whilst two  
258 volunteers also developed a mild-moderate anaemia post-diagnosis. With regards to the latter, one  
259 normalized within 28 days of challenge, the other persisted at grade 1 at dC+90 (102 g/L) and so was  
260 referred to their medical practitioner for ongoing monitoring as a precautionary measure (**Table S5C** and  
261 **Fig. S6C**). The only notable change in blood chemistry was a transient grade 1-2 rise in the ALT in 4/6  
262 volunteers, captured consistently at 6 days post-treatment (**Fig. 4F**). All fully resolved to pre-challenge  
263 levels with no associated abnormalities in other indices of liver function (**Fig. S6C, Table S5D**). Finally, we  
264 also confirmed CMV and EBV sero-status of all volunteers pre- and post-CHMI. All six volunteers were  
265 EBV sero-positive pre-CHMI and three were CMV sero-positive. Of the three CMV sero-negative  
266 volunteers, one withdrew consent and left the trial at C+28 and was therefore not re-tested, whilst the  
267 other two remained sero-negative when re-tested at C+90.

268

## 269 **Antibody responses to blood-stage merozoite antigens post-CHMI**

270 We next assessed for the induction of serum IgG antibody responses post-CHMI against two well-known  
271 blood-stage merozoite antigens – *P. vivax* merozoite surface protein 1 C-terminal 19 kDa region  
272 (PvMSP1<sub>19</sub>) and *P. vivax* Duffy-binding protein region II (PvDBP\_RII). All volunteers had detectable IgG  
273 against PvMSP1<sub>19</sub> post-CHMI, with similar results seen in the VAC068 mosquito-bite sporozoite CHMI  
274 study and the VAC069A blood-stage CHMI study (**Fig. 5A**). However, there were no detectable responses  
275 post-CHMI against PvDBP\_RII in any of the volunteers, in contrast to positive control samples from a  
276 cohort of healthy UK adult volunteers previously vaccinated with the PvDBP\_RII antigen (29) which were  
277 included here for comparison (**Fig. 5B**).

278

## 279 **PvW1 genome assembly allows resolution of complex multi-gene families**

280 Finally, we produced a genome assembly for PvW1 by using a hybrid assembly method which combined  
281 long PacBio reads with short Illumina reads. The PvW1 genome assembled into 14 scaffolds (the 14 *P.*  
282 *vivax* chromosomes), and is comparable in both assembly size and number of genes to the highest  
283 quality existing *P. vivax* assembly, PvP01 (30) (**Table 1**). The PvW1 assembly has fewer unassigned  
284 scaffolds than any other assembly, indicating the completeness of the assembled genome and the  
285 benefits of using a combination of long and short reads; note the PvP01, PvC01 and PvT01 were all  
286 assembled using Illumina data only (30), while the original reference, PvSalvador-1 (Sall), was created  
287 using capillary sequence data (31).

288 The high quality of the PvW1 assembly allowed us to identify 1145 *Vivax* interspersed repeat (VIR) genes  
289 within the genome, comparable in number to the PvP01 genome. Computational studies have shown  
290 that the VIR genes from different *P. vivax* isolates can be grouped into a number of clusters, and it is  
291 possible that genes within clusters may be performing a similar function (30, 32). Cluster analysis  
292 showed that the majority of the 1145 PvW1 VIR proteins could be clustered into groups with VIRs from  
293 the PvP01, PvT01, PvC01 and Sall strains (**Fig. 6**), with no evidence that specific clusters are restricted to  
294 specific genomes or geographical regions.

295 Similarly, we resolved other smaller but still highly polymorphic multigene families such as the  
296 merozoite surface protein 3 (MSP3) family. These proteins are expressed on the surface of the invasive  
297 merozoite and are known to be highly polymorphic both in sequence and gene number between  
298 isolates. We compared the organization of the MSP3 multigene family in PvW1 to *P. vivax* isolates:  
299 PvP01 (30) and Sall, India-7, North Korean, Mauritania-1 and Brazil-1 (33). Genes flanking the MSP3

300 cluster (PVX\_097665 and PVX\_097740) are syntenic across all isolates, as are MSP3.1, MSP3.2, MSP3.3,  
301 MSP3.G, MSP3.10 and MSP3.11. There is however clearly variability in the central region of the MSP3  
302 region, with MSP3.4, MSP3.5, MSP3.6, MSP3.7, MSP3.8 and MSP3.9 all present in some isolates but not  
303 others (**Fig. S7**). The arrangement of the PvW1 MSP3 cluster appears identical to that of PvP01.

304

### 305 **PvW1 vaccine candidate and drug resistance associated genes**

306 The quality of the PvW1 genome also makes it easy to obtain and analyze potential vaccine targets,  
307 which we did for three high profile candidates (34), comparing the PvW1 sequence with those from  
308 PvP01 and Sall. The sporozoite-stage target circumsporozoite protein (PvCSP) is known to contain one of  
309 two major types of repeat called VK210 and VK247 (35, 36), with this heterogeneity an important factor  
310 for vaccine design. PvW1 contains VK210 repeats, the most prevalent form worldwide (**Fig. S8A**). The  
311 sequence of the transmission-stage candidate Pvs25 is highly conserved between PvW1 and other  
312 genomes, apart from the commonly variable amino acids 130 and 131 within the third epidermal growth  
313 factor (EGF)-like domain (**Fig. S8B**). Finally, we reviewed the PvDBP sequence given two vaccine  
314 candidates targeting region II are currently in early-phase clinical trials (29, 37). PvDBP in PvW1 has  
315 multiple polymorphisms with 10 in region II, including the DEK epitope (38), as compared to the Sall  
316 sequence used in the current clinical vaccines (29, 37). Like PvDBP from Sall, this gene in PvW1 also has  
317 a nine amino acid deletion (downstream of region II) that is not present in PvP01 (**Fig. S8C**). As well  
318 varying at a sequence level, PvDBP is also known to vary between isolates in copy number, with some  
319 isolates containing multiple copies (39, 40) now linked to evasion of humoral immunity (41). We  
320 therefore used Illumina read mapping across the PvW1 genome assembly to check for copy number  
321 variation of genes. Here, if regions of the genome are present in multiple copies then the read coverage  
322 over that region would be higher than the surrounding regions. There was no evidence for increased  
323 coverage at either PvDBP or its homologue PvDBP2 (also called *P. vivax* erythrocyte-binding protein,  
324 PvEBP), suggesting both are present at a single copy within the PvW1 genome (**Fig. S9A-B**). We also  
325 looked at an uncharacterized gene on chromosome 14, homologous to PVX\_101445 / PvP01\_1468200,  
326 which has been shown to be duplicated in some isolates (42). This gene is also present in a single copy in  
327 PvW1 (**Fig. S9D**).

328 Drug resistance is not as well characterized in *P. vivax* as in *P. falciparum*, but several genes and  
329 polymorphisms have been associated with resistance in field studies. We therefore examined the  
330 sequences of four genes within the PvW1 genome that have been associated with drug resistance:

331 dihydrofolate reductase (*PvDHFR*), dihydropteroate synthetase (*PvDHPS*), chloroquine resistance  
332 transporter (*PvCRT*) and multidrug resistance transporter 1 (*PvMDR1*). The PvW1 *PvDHFR* gene encodes  
333 a protein with the quadruple mutation F57L/S58R/T61M/S117T that has been linked to pyrimethamine  
334 resistance (43), whereas *PvDHPS* showed no mutations previously associated with sulfadoxine resistance  
335 (44). The molecular basis of *P. vivax* chloroquine resistance is less clear, although there is some evidence  
336 that mutations in *PvCRT* (K10 insertion) and *PvMDR1* (Y976F mutation) may be involved (45-47). Neither  
337 of these mutations are present in the PvW1 *PvCRT* and *PvMDR1* genes. It is important to note that both  
338 Riamet® and Malarone antimalarials were used with 100% treatment success rates in the VAC068 and  
339 VAC069A studies (both volunteers in VAC068 and 5/6 volunteers in VAC069A received Riamet®, 1/6  
340 received Malarone), and none of the polymorphisms identified have been associated with resistance to  
341 either of these drugs.

## 342 Discussion

343 Here we undertook CHMI model development for *P. vivax* and established a new PvW1 clonal isolate  
344 from Thailand. Our methodology elected to focus on a mosquito-bite CHMI protocol to provide the  
345 initial source of blood-stage parasites for the cryopreserved stabilate. The main advantages here (over  
346 parasites donated by returning travellers) included the ability to control the parasite source, the  
347 recruitment of suitable healthy volunteers (especially with regard to health screening and universal  
348 donor blood group) and logistical timing. We also created the blood stabilate as close as possible to the  
349 mosquito-stage, with only ~3 cycles of replication from the liver (given it is known that mosquitoes reset  
350 parasite virulence (24)). If parasites had been cryopreserved from returning travellers or chronically-  
351 infected adults in an endemic setting they would have been selected over many rounds of asexual  
352 replication *in vivo* before creating the stabilate. This diminishes the criticism that blood-stage CHMI is  
353 not the natural route of infection. Notably our real-time assessment of parasite genotypes in the  
354 infected mosquitoes in Thailand identified only one clonal infection out of three tested. In future it will  
355 likely be necessary to screen more infected patient samples if parasite clones with specific genotypes  
356 are desired. It is also probable that this clonal infection resulted from a single relapsing hypnozoite in  
357 the patient, given natural infections are frequently polyclonal, arising from primary infections with  
358 multiple genotypes and meiotic siblings produced in the mosquito and/or multiple heterologous  
359 hypnozoites relapsing at a similar time (48-50).

360 The VAC068 mosquito-bite trial demonstrated feasibility and safety of this CHMI model for the first time  
361 at a European site, albeit in only two healthy adult UK volunteers. Both were successfully infected, with  
362 parasites first detectable by qPCR on dC+8.5 and the first wave of blood-stage parasitemia peaking  
363 around dC+9. This is largely consistent with data from humanized mouse models suggesting that the  
364 complete maturation of *P. vivax* liver stages and exo-erythrocytic merozoite release occurs between  
365 days 9 and day 10 post-sporozoite infection (51). Growth of blood-stage parasitemia was subsequently  
366 similar in the two volunteers, with both meeting criteria to donate blood on dC+14, prior to radical cure  
367 treatment with Riamet® followed by primaquine. Both volunteers were screened to have CYP2D6  
368 genotypes predicted to be extensive metabolizer phenotypes of primaquine, and as of ~3 years' long-  
369 term follow-up, no relapse of infection has been documented.

370 Cryopreservation of the iRBC stabilate was performed successfully, however, given *P. vivax* cannot be  
371 cultured long-term *in vitro* it proved challenging to confirm parasite viability following thaw of the  
372 frozen stabilate, especially given the relatively low level of parasitemia achieved by CHMI in non-

373 immune adults. However, given the stabilate from Donor 1 showed demonstrable growth *in vitro* using a  
374 short-term culture assay, we elected to proceed with this material for onward testing. Poor parasite  
375 recovery from Donor 2 could be associated with the predominant lifecycle stage at the time of  
376 cryopreservation; here microscopy records indicated the presence of more schizonts and a smaller  
377 proportion of early ring-stage trophozoites in comparison to Donor 1. Previous evidence suggests that  
378 the late asexual intra-erythrocytic parasites are not viable after cryopreservation with glycerolyte (52),  
379 and this may have led to the poor recovery of live parasites in Donor 2's stabilate.

380 Previous reports of blood-stage CHMI using *P. vivax* have used one vial of cryopreserved stabilate to  
381 infect one volunteer (19-21), in contrast to similar studies with the stabilate of 3D7 clone *P. falciparum*  
382 whereby a single vial is diluted and routinely used to infect ~20-30 volunteers (16, 53). Thawing many  
383 vials to undertake CHMI in larger cohorts of volunteers, e.g. for vaccine efficacy trials, brings many  
384 practical difficulties and, in turn, more rapidly depletes the bank of cryopreserved stabilate which is a  
385 finite resource. Conserving vials and building up a long-term safety database of the challenge agent for  
386 future use across many clinical studies is also preferable. Consequently, we assessed three different  
387 doses of the PvW1 blood-stage inoculum in the VAC069A study, with two volunteers receiving each  
388 dose. All six volunteers were successfully diagnosed at similar levels of blood-stage parasitemia within  
389 12-16 days. Importantly, these data suggest that blood-stage CHMI trials in larger volunteer cohorts are  
390 now practical and feasible, whilst preserving the bank of PvW1 parasites for the long-term.

391 The AE profiles of both the mosquito-bite and blood-stage CHMI with PvW1 were highly comparable to  
392 previous reports of both models in malaria-naïve/non-immune adults using other isolates of *P. vivax* at  
393 the Colombian (8-10) or Australian sites (19-23). No SAEs occurred in either trial and all drug treatments  
394 were successful. Symptoms consistent with malaria were experienced and peaked post-treatment prior  
395 to resolving within a few days. We also observed transient thrombocytopenia and lymphocytopenia, as  
396 well as rises in ALT six days post-treatment, consistent with the reports of other sites undertaking *P.*  
397 *vivax* CHMI (9, 10, 54) and with no apparent impact on volunteer safety. We also observed consistent  
398 sero-conversion to PvMSP<sub>119</sub> post-CHMI in all volunteers, as reported in the Colombian CHMI trials (10,  
399 55), but no detectable responses to PvDBP\_RII. These data are in line with our similar studies of *P.*  
400 *falciparum* CHMI, with sero-conversion of malaria-naïve adults observed to immuno-dominant  
401 merozoite surface proteins following primary acute malaria exposure, but not to more transiently  
402 exposed RBC invasion ligands (56, 57).

403 Following mosquito-bite CHMI we observed ~10-fold growth in blood-stage parasitemia per 48 hours,  
404 consistent with other reports for *P. vivax* (20), as well as our experience with *P. falciparum* (16, 53).  
405 Interestingly, however, the average PMR was lower (~5.5-fold growth per 48 hours) following blood-  
406 stage CHMI with the same parasite. There was no obvious effect of challenge dose or Duffy blood group  
407 sero-phenotype on the PMR, the latter consistent with our observations *in vitro* using *P. knowlesi*  
408 parasites transgenic for PvDBP (58). However, Duffy blood group sero-phenotype has been linked to  
409 susceptibility of *P. vivax* clinical malaria following natural infection (59). Consequently CHMI studies in  
410 larger numbers of volunteers will be required to more stringently assess for any relationships between  
411 blood group antigens and the observed PMR, and to more accurately establish the natural variability in  
412 the PMR observed in malaria-naïve adults. A second striking difference between the two CHMI models  
413 was the apparent minimal gametocytemia following mosquito-bite CHMI, in contrast to blood-stage  
414 CHMI. In the latter, the *pvs25* transcripts (a marker of mature female gametocytes) were reliably  
415 detected in all six volunteers, reaching comparable levels to those reported in other *P. vivax* blood-stage  
416 CHMI studies (19, 20). Notably, poor transmission to mosquitoes was reported in another *P. vivax*  
417 mosquito-bite CHMI trial, consistent with our data here (60). Interestingly, a more recent study  
418 comparing the same two CHMI models with *P. falciparum* reported the same finding (17). Why blood-  
419 stage CHMI appears to lead to much greater gametocytemia than mosquito-bite CHMI, despite reaching  
420 comparable levels of overall parasitemia by the time of diagnosis, remains to be determined. However,  
421 this might reflect the greater number of asexual growth cycles since liver egress, or a longer time to  
422 diagnosis allowing for an extended window for conversion of asexual parasites.

423 Finally, we proceeded to undertake a genomic analysis of the new *P. vivax* PvW1 clone. The need to  
424 drug treat volunteer infections at relatively low parasitemia limited the amount of PvW1 parasite DNA  
425 that could be isolated for sequencing. Nevertheless, a very high quality genome assembly for PvW1 was  
426 created by using a hybrid assembly method which combined long PacBio reads with short Illumina  
427 reads. The PacBio library was created using low-input PacBio technology developed to create a genome  
428 assembly from a single mosquito (61), and is to our knowledge the first time that this has been applied  
429 to *Plasmodium* parasites. Our goal is that the PvW1 clone will become a valuable tool for vaccine  
430 discovery, drug testing and assessment of *P. vivax* *in vivo* immuno-biology. Accurate assessment of both  
431 the sequence and copy number of vaccine candidate antigens within the PvW1 genome will thus be  
432 critical in designing future vaccine immunogens and interpreting CHMI efficacy studies. The high quality  
433 of the PvW1 assembly allowed us to easily report on leading vaccine candidate antigens, analyze genes  
434 and polymorphisms associated with drug resistance in field studies, and resolve 1145 VIR genes as well



435 as the smaller polymorphic PvMSP3 multigene family. Although the function of the highly variable  
436 subtelomeric multigene VIR family is not well defined, related genes are found in high numbers in most  
437 *Plasmodium* species which infect humans, monkeys and rodents, and some are thought to be involved  
438 in immune evasion, including by directly binding to and down-regulating natural killer (NK) cell ligands  
439 (62). Our cluster analysis will now enable comparison of gene function within and between clusters, and  
440 should help in the future elucidation of the function of the VIR gene family.

441 In conclusion, we have developed a mosquito-transmitted stabilate using a new clonal field isolate of *P.*  
442 *vivax* and combined new methodologies for parasite isolation and ultra-low input PacBio sequencing to  
443 assemble a reference-quality genome for CHMI. This has i) revealed polymorphisms in leading drug and  
444 vaccine targets that can now be functionally tested *in vivo* with PvW1 and ii) used a hybrid  
445 PacBio/Illumina genome assembly technique to identify 1145 unique VIR genes. This will allow for *in vivo*  
446 switching and selection of multi-gene families to be measured in *P. vivax* in the same way as has been  
447 done for *P. falciparum* (18). This has allowed us to open up many new research avenues, and in the first  
448 instance, we have used this model to investigate myeloid cell activation, systemic inflammation, and the  
449 fate and function of human T cells during a first-in-life *P. vivax* infection (63). The PvW1 parasite should  
450 prove to be an invaluable resource for the wider malaria community.

451 **References**

- 452 1. Gething PW, Elyazar IR, Moyes CL, Smith DL, Battle KE, Guerra CA, *et al.* A long neglected world  
453 malaria map: *Plasmodium vivax* endemicity in 2010. *PLoS Negl Trop Dis.* 2012;6(9):e1814.
- 454 2. Baird JK. Evidence and implications of mortality associated with acute *Plasmodium vivax*  
455 malaria. *Clin Microbiol Rev.* 2013;26(1):36-57.
- 456 3. Galinski MR, and Barnwell JW. *Plasmodium vivax*: who cares? *Malar J.* 2008;7 Suppl 1:S9.
- 457 4. Mueller I, Galinski MR, Baird JK, Carlton JM, Kochar DK, Alonso PL, *et al.* Key gaps in the  
458 knowledge of *Plasmodium vivax*, a neglected human malaria parasite. *Lancet Infect Dis.*  
459 2009;9(9):555-66.
- 460 5. White NJ. Determinants of relapse periodicity in *Plasmodium vivax* malaria. *Malar J.*  
461 2011;10:297.
- 462 6. Stanisic DI, McCarthy JS, and Good MF. Controlled Human Malaria Infection: Applications,  
463 Advances, and Challenges. *Infect Immun.* 2018;86(1).
- 464 7. Payne RO, Griffin PM, McCarthy JS, and Draper SJ. *Plasmodium vivax* Controlled Human Malaria  
465 Infection - Progress and Prospects. *Trends Parasitol.* 2017;33(2):141-50.
- 466 8. Herrera S, Fernandez O, Manzano MR, Murrain B, Vergara J, Blanco P, *et al.* Successful  
467 sporozoite challenge model in human volunteers with *Plasmodium vivax* strain derived from  
468 human donors. *Am J Trop Med Hyg.* 2009;81(5):740-6.
- 469 9. Herrera S, Solarte Y, Jordan-Villegas A, Echavarría JF, Rocha L, Palacios R, *et al.* Consistent safety  
470 and infectivity in sporozoite challenge model of *Plasmodium vivax* in malaria-naïve human  
471 volunteers. *Am J Trop Med Hyg.* 2011;84(2 Suppl):4-11.
- 472 10. Arevalo-Herrera M, Forero-Pena DA, Rubiano K, Gomez-Hincapie J, Martinez NL, Lopez-Perez M,  
473 *et al.* *Plasmodium vivax* sporozoite challenge in malaria-naïve and semi-immune Colombian  
474 volunteers. *PLoS One.* 2014;9(6):e99754.
- 475 11. Arevalo-Herrera M, Vasquez-Jimenez JM, Lopez-Perez M, Vallejo AF, Amado-Garavito AB,  
476 Cespedes N, *et al.* Protective Efficacy of *Plasmodium vivax* Radiation-Attenuated Sporozoites in  
477 Colombian Volunteers: A Randomized Controlled Trial. *PLoS Negl Trop Dis.*  
478 2016;10(10):e0005070.
- 479 12. Bennett JW, Yadava A, Tosh D, Sattabongkot J, Komisar J, Ware LA, *et al.* Phase 1/2a Trial of  
480 *Plasmodium vivax* Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naïve Adults: Safety,  
481 Immunogenicity, and Efficacy. *PLoS Negl Trop Dis.* 2016;10(2):e0004423.
- 482 13. Bennett JW, Pybus BS, Yadava A, Tosh D, Sousa JC, McCarthy WF, *et al.* Primaquine Failure and  
483 Cytochrome P-450 2D6 in *Plasmodium vivax* Malaria. *N Engl J Med.* 2013;369(14):1381-2.
- 484 14. Duncan CJ, and Draper SJ. Controlled human blood stage malaria infection: current status and  
485 potential applications. *Am J Trop Med Hyg.* 2012;86(4):561-5.
- 486 15. Engwerda CR, Minigo G, Amante FH, and McCarthy JS. Experimentally induced blood stage  
487 malaria infection as a tool for clinical research. *Trends Parasitol.* 2012;28(11):515-21.
- 488 16. Payne RO, Milne KH, Elias SC, Edwards NJ, Douglas AD, Brown RE, *et al.* Demonstration of the  
489 Blood-Stage Controlled Human Malaria Infection Model to Assess Efficacy of the *Plasmodium*  
490 *falciparum* AMA1 Vaccine FMP2.1/AS01. *J Infect Dis.* 2016;213(11):1743-51.
- 491 17. Alkema M, Reuling IJ, de Jong GM, Lanke K, Coffeng LE, van Gemert GJ, *et al.* A randomized  
492 clinical trial to compare *P. falciparum* gametocytaemia and infectivity following blood-stage or  
493 mosquito bite induced controlled malaria infection. *J Infect Dis.* 2020.
- 494 18. Milne K, Ivens A, Reid AJ, Lotkowska ME, O'Toole A, Sankaranarayanan G, *et al.* Mapping  
495 immune variation and var gene switching in naïve hosts infected with *Plasmodium falciparum*.  
496 *eLife.* 2021;10.

- 497 19. McCarthy JS, Griffin PM, Sekuloski S, Bright AT, Rockett R, Looke D, et al. Experimentally induced  
498 blood-stage Plasmodium vivax infection in healthy volunteers. *J Infect Dis.* 2013;208(10):1688-  
499 94.
- 500 20. Griffin P, Pasay C, Elliott S, Sekuloski S, Sikulu M, Hugo L, et al. Safety and Reproducibility of a  
501 Clinical Trial System Using Induced Blood Stage Plasmodium vivax Infection and Its Potential as a  
502 Model to Evaluate Malaria Transmission. *PLoS Negl Trop Dis.* 2016;10(12):e0005139.
- 503 21. Collins KA, Wang CY, Adams M, Mitchell H, Rampton M, Elliott S, et al. A controlled human  
504 malaria infection model enabling evaluation of transmission-blocking interventions. *J Clin Invest.*  
505 2018;128(4):1551-62.
- 506 22. Collins KA, Abd-Rahman AN, Marquart L, Ballard E, Gobeau N, Griffin P, et al. Antimalarial  
507 activity of artefenomel against asexual parasites and transmissible gametocytes during  
508 experimental blood-stage Plasmodium vivax infection. *J Infect Dis.* 2020.
- 509 23. Odedra A, Mudie K, Kennedy G, Watts RE, Rossignol E, Mitchell H, et al. Safety and feasibility of  
510 apheresis to harvest and concentrate parasites from subjects with induced blood stage  
511 Plasmodium vivax infection. *Malar J.* 2021;20(1):43.
- 512 24. Spence PJ, Jarra W, Levy P, Reid AJ, Chappell L, Brugat T, et al. Vector transmission regulates  
513 immune control of Plasmodium virulence. *Nature.* 2013;498(7453):228-31.
- 514 25. Miller LH, Mason SJ, Clyde DF, and McGinniss MH. The resistance factor to Plasmodium vivax in  
515 blacks. The Duffy-blood-group genotype, FyFy. *N Engl J Med.* 1976;295(6):302-4.
- 516 26. Baird JK. 8-Aminoquinoline Therapy for Latent Malaria. *Clin Microbiol Rev.* 2019;32(4).
- 517 27. Rebsamen MC, Desmeules J, Daali Y, Chiappe A, Diemand A, Rey C, et al. The AmpliChip CYP450  
518 test: cytochrome P450 2D6 genotype assessment and phenotype prediction. *Pharmacogenomics*  
519 *J.* 2009;9(1):34-41.
- 520 28. Douglas AD, Edwards NJ, Duncan CJ, Thompson FM, Sheehy SH, O'Hara GA, et al. Comparison of  
521 Modeling Methods to Determine Liver-to-blood Inocula and Parasite Multiplication Rates During  
522 Controlled Human Malaria Infection. *J Infect Dis.* 2013;208(2):340-5.
- 523 29. Payne RO, Silk SE, Elias SC, Milne KH, Rawlinson TA, Llewellyn D, et al. Human vaccination  
524 against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies. *JCI*  
525 *Insight.* 2017;2(12):93683.
- 526 30. Auburn S, Bohme U, Steinbiss S, Trimarsanto H, Hostetler J, Sanders M, et al. A new Plasmodium  
527 vivax reference sequence with improved assembly of the subtelomeres reveals an abundance of  
528 pir genes. *Wellcome open research.* 2016;1:4.
- 529 31. Carlton JM, Adams JH, Silva JC, Bidwell SL, Lorenzi H, Caler E, et al. Comparative genomics of the  
530 neglected human malaria parasite Plasmodium vivax. *Nature.* 2008;455(7214):757-63.
- 531 32. Lopez FJ, Bernabeu M, Fernandez-Becerra C, and del Portillo HA. A new computational approach  
532 redefines the subtelomeric vir superfamily of Plasmodium vivax. *BMC Genomics.* 2013;14:8.
- 533 33. Rice BL, Acosta MM, Pacheco MA, Carlton JM, Barnwell JW, and Escalante AA. The origin and  
534 diversification of the merozoite surface protein 3 (msp3) multi-gene family in Plasmodium vivax  
535 and related parasites. *Mol Phylogenet Evol.* 2014;78:172-84.
- 536 34. Draper SJ, Sack BK, King CR, Nielsen CM, Rayner JC, Higgins MK, et al. Malaria Vaccines: Recent  
537 Advances and New Horizons. *Cell Host Microbe.* 2018;24(1):43-56.
- 538 35. Arnot DE, Barnwell JW, Tam JP, Nussenzweig V, Nussenzweig RS, and Enea V. Circumsporozoite  
539 protein of Plasmodium vivax: gene cloning and characterization of the immunodominant  
540 epitope. *Science.* 1985;230(4727):815-8.
- 541 36. Rosenberg R, Wirtz RA, Lanar DE, Sattabongkot J, Hall T, Waters AP, et al. Circumsporozoite  
542 protein heterogeneity in the human malaria parasite Plasmodium vivax. *Science.*  
543 1989;245(4921):973-6.

- 544 37. Singh K, Mukherjee P, Shakri AR, Singh A, Pandey G, Bakshi M, et al. Malaria vaccine candidate  
545 based on Duffy-binding protein elicits strain transcending functional antibodies in a Phase I trial.  
546 *NPJ Vaccines*. 2018;3:48.
- 547 38. Chen E, Salinas ND, Ntumngia FB, Adams JH, and Tolia NH. Structural Analysis of the Synthetic  
548 Duffy Binding Protein (DBP) Antigen DEKnull Relevant for Plasmodium vivax Malaria Vaccine  
549 Design. *PLoS Negl Trop Dis*. 2015;9(3):e0003644.
- 550 39. Menard D, Chan ER, Benedet C, Ratsimbaoa A, Kim S, Chim P, et al. Whole genome sequencing  
551 of field isolates reveals a common duplication of the Duffy binding protein gene in Malagasy  
552 Plasmodium vivax strains. *PLoS Negl Trop Dis*. 2013;7(11):e2489.
- 553 40. Hostetler JB, Lo E, Kanjee U, Amaratunga C, Suon S, Sreng S, et al. Independent Origin and  
554 Global Distribution of Distinct Plasmodium vivax Duffy Binding Protein Gene Duplications. *PLoS  
555 Negl Trop Dis*. 2016;10(10):e0005091.
- 556 41. Popovici J, Roesch C, Carias LL, Khim N, Kim S, Vantaux A, et al. Amplification of Duffy binding  
557 protein-encoding gene allows Plasmodium vivax to evade host anti-DBP humoral immunity. *Nat  
558 Commun*. 2020;11(1):953.
- 559 42. Pearson RD, Amato R, Auburn S, Miotto O, Almagro-Garcia J, Amaratunga C, et al. Genomic  
560 analysis of local variation and recent evolution in Plasmodium vivax. *Nat Genet*. 2016;48(8):959-  
561 64.
- 562 43. Auliff AM, Adams JH, O'Neil MT, and Cheng Q. Defining the role of mutations in Plasmodium  
563 vivax dihydrofolate reductase-thymidylate synthase gene using an episomal Plasmodium  
564 falciparum transfection system. *Antimicrob Agents Chemother*. 2010;54(9):3927-32.
- 565 44. Pornthanakasem W, Riengrunroj P, Chitnumsub P, Ittarat W, Kongkasuriyachai D, Uthaipibull C,  
566 et al. Role of Plasmodium vivax Dihydropteroate Synthase Polymorphisms in Sulfa Drug  
567 Resistance. *Antimicrob Agents Chemother*. 2016;60(8):4453-63.
- 568 45. Suwanarusk R, Russell B, Chavchich M, Chalfein F, Kenangalem E, Kosaisavee V, et al.  
569 Chloroquine resistant Plasmodium vivax: in vitro characterisation and association with  
570 molecular polymorphisms. *PLoS One*. 2007;2(10):e1089.
- 571 46. Suwanarusk R, Chavchich M, Russell B, Jaidee A, Chalfein F, Barends M, et al. Amplification of  
572 pvmdr1 associated with multidrug-resistant Plasmodium vivax. *J Infect Dis*. 2008;198(10):1558-  
573 64.
- 574 47. Lu F, Lim CS, Nam DH, Kim K, Lin K, Kim TS, et al. Genetic polymorphism in pvmdr1 and pvcr-t  
575 genes in relation to in vitro drug susceptibility of Plasmodium vivax isolates from malaria-  
576 endemic countries. *Acta Trop*. 2011;117(2):69-75.
- 577 48. Chen N, Auliff A, Rieckmann K, Gatton M, and Cheng Q. Relapses of Plasmodium vivax infection  
578 result from clonal hypnozoites activated at predetermined intervals. *J Infect Dis*.  
579 2007;195(7):934-41.
- 580 49. Imwong M, Snounou G, Pukrittayakamee S, Tanomsing N, Kim JR, Nandy A, et al. Relapses of  
581 Plasmodium vivax infection usually result from activation of heterologous hypnozoites. *J Infect  
582 Dis*. 2007;195(7):927-33.
- 583 50. Bright AT, Manary MJ, Tewhey R, Arango EM, Wang T, Schork NJ, et al. A high resolution case  
584 study of a patient with recurrent Plasmodium vivax infections shows that relapses were caused  
585 by meiotic siblings. *PLoS Negl Trop Dis*. 2014;8(6):e2882.
- 586 51. Mikolajczak SA, Vaughan AM, Kangwanransan N, Roobsoong W, Fishbaugher M,  
587 Yimamnuaychok N, et al. Plasmodium vivax liver stage development and hypnozoite persistence  
588 in human liver-chimeric mice. *Cell Host Microbe*. 2015;17(4):526-35.
- 589 52. Malaria parasite strain characterization, cryopreservation, and banking of isolates: a WHO  
590 memorandum. *Bull World Health Organ*. 1981;59(4):537-48.

- 591 53. Minassian AM, Silk SE, Barrett JR, Nielsen CM, Miura K, Diouf A, et al. Reduced blood-stage  
592 malaria growth and immune correlates in humans following RH5 vaccination. *Med*. 2021;2:1-19.
- 593 54. Odedra A, Webb L, Marquart L, Britton LJ, Chalon S, Moehrle JJ, et al. Liver Function Test  
594 Abnormalities in Experimental and Clinical Plasmodium vivax Infection. *Am J Trop Med Hyg*.  
595 2020;103(5):1910-7.
- 596 55. Arevalo-Herrera M, Lopez-Perez M, Dotsey E, Jain A, Rubiano K, Felgner PL, et al. Antibody  
597 Profiling in Naive and Semi-immune Individuals Experimentally Challenged with Plasmodium  
598 vivax Sporozoites. *PLoS Negl Trop Dis*. 2016;10(3):e0004563.
- 599 56. Biswas S, Choudhary P, Elias SC, Miura K, Milne KH, de Cassan SC, et al. Assessment of Humoral  
600 Immune Responses to Blood-Stage Malaria Antigens following ChAd63-MVA Immunization,  
601 Controlled Human Malaria Infection and Natural Exposure. *PLoS One*. 2014;9(9):e107903.
- 602 57. Hodgson SH, Llewellyn D, Silk SE, Milne KH, Elias SC, Miura K, et al. Changes in Serological  
603 Immunology Measures in UK and Kenyan Adults Post-controlled Human Malaria Infection. *Front*  
604 *Microbiol*. 2016;7:1604.
- 605 58. Mohring F, Hart MN, Rawlinson TA, Henrici R, Charleston JA, Diez Benavente E, et al. Rapid and  
606 iterative genome editing in the malaria parasite Plasmodium knowlesi provides new tools for P.  
607 vivax research. *eLife*. 2019;8.
- 608 59. King CL, Adams JH, Xianli J, Grimberg BT, McHenry AM, Greenberg LJ, et al. Fy(a)/Fy(b) antigen  
609 polymorphism in human erythrocyte Duffy antigen affects susceptibility to Plasmodium vivax  
610 malaria. *Proc Natl Acad Sci U S A*. 2011;108(50):20113-8.
- 611 60. Vallejo AF, Garcia J, Amado-Garavito AB, Arevalo-Herrera M, and Herrera S. Plasmodium vivax  
612 gametocyte infectivity in sub-microscopic infections. *Malar J*. 2016;15:48.
- 613 61. Kingan SB, Heaton H, Cudini J, Lambert CC, Baybayan P, Galvin BD, et al. A High-Quality De novo  
614 Genome Assembly from a Single Mosquito Using PacBio Sequencing. *Genes (Basel)*. 2019;10(1).
- 615 62. Harrison TE, Morch AM, Felce JH, Sakoguchi A, Reid AJ, Arase H, et al. Structural basis for RIFIN-  
616 mediated activation of LILRB1 in malaria. *Nature*. 2020;587(7833):309-12.
- 617 63. Bach F, Sandoval DM, Mazurczyk M, Themistocleous Y, Rawlinson TA, Kemp A, et al. Parasite  
618 species regulates T cell activation in human malaria. *medRxiv*. 2021:2021.03.22.21252810.
- 619 64. Nanfack Minkeu F, and Vernick KD. A Systematic Review of the Natural Virome of Anopheles  
620 Mosquitoes. *Viruses*. 2018;10(5).
- 621 65. Miguel-Oteo M, Jiram AI, Ta-Tang TH, Lanza M, Hisam S, and Rubio JM. Nested multiplex PCR for  
622 identification and detection of human Plasmodium species including Plasmodium knowlesi.  
623 *Asian Pac J Trop Med*. 2017;10(3):299-304.
- 624 66. Jacob CG, Thuy-Nhien N, Mayxay M, Maude RJ, Quang HH, Hongvanthong B, et al. Genetic  
625 surveillance in the Greater Mekong Subregion and South Asia to support malaria control and  
626 elimination. *medRxiv*. 2020:2020.07.23.20159624.
- 627 67. Pybus BS, Sousa JC, Jin X, Ferguson JA, Christian RE, Barnhart R, et al. CYP450 phenotyping and  
628 accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug  
629 primaquine. *Malar J*. 2012;11:259.
- 630 68. Joint Ukbts/Hpa Professional Advisory Committee. *Guidelines for the blood transfusion services*  
631 *in the United Kingdom*. 2013.
- 632 69. Cervia JS, Wenz B, and Ortolano GA. Leukocyte reduction's role in the attenuation of infection  
633 risks among transfusion recipients. *Clin Infect Dis*. 2007;45(8):1008-13.
- 634 70. Hodgson SH, Juma E, Salim A, Magiri C, Kimani D, Njenga D, et al. Evaluating controlled human  
635 malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium  
636 falciparum using sporozoites administered by intramuscular injection. *Front Microbiol*.  
637 2014;5:686.

- 638 71. Devi YS, Mukherjee P, Yazdani SS, Shakri AR, Mazumdar S, Pandey S, et al. Immunogenicity of  
639 Plasmodium vivax combination subunit vaccine formulated with human compatible adjuvants in  
640 mice. *Vaccine*. 2007;25(28):5166-74.
- 641 72. Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. 2011.  
642 2011;17(1):3.
- 643 73. Sayers EW, Agarwala R, Bolton EE, Brister JR, Canese K, Clark K, et al. Database resources of the  
644 National Center for Biotechnology Information. *Nucleic Acids Res*. 2019;47(D1):D23-D8.
- 645 74. Buchfink B, Xie C, and Huson DH. Fast and sensitive protein alignment using DIAMOND. *Nature*  
646 *methods*. 2015;12(1):59-60.
- 647 75. Li H. Minimap2: pairwise alignment for nucleotide sequences. *Bioinformatics*. 2018;34(18):3094-  
648 100.
- 649 76. Wood DE, and Salzberg SL. Kraken: ultrafast metagenomic sequence classification using exact  
650 alignments. *Genome Biol*. 2014;15(3):R46.
- 651 77. El-Metwally S, Zakaria M, and Hamza T. LightAssembler: fast and memory-efficient assembly  
652 algorithm for high-throughput sequencing reads. *Bioinformatics*. 2016;32(21):3215-23.
- 653 78. Koren S, Walenz BP, Berlin K, Miller JR, Bergman NH, and Phillippy AM. Canu: scalable and  
654 accurate long-read assembly via adaptive k-mer weighting and repeat separation. *Genome Res*.  
655 2017;27(5):722-36.
- 656 79. Bonfield JK, and Whitwham A. Gap5--editing the billion fragment sequence assembly.  
657 *Bioinformatics*. 2010;26(14):1699-703.
- 658 80. Walker BJ, Abeel T, Shea T, Priest M, Abouelliel A, Sakthikumar S, et al. Pilon: an integrated tool  
659 for comprehensive microbial variant detection and genome assembly improvement. *PLoS One*.  
660 2014;9(11):e112963.
- 661 81. Hunt M, Silva ND, Otto TD, Parkhill J, Keane JA, and Harris SR. Circlator: automated  
662 circularization of genome assemblies using long sequencing reads. *Genome Biol*. 2015;16:294.
- 663 82. Waterhouse RM, Seppey M, Simao FA, Manni M, Ioannidis P, Klioutchnikov G, et al. BUSCO  
664 Applications from Quality Assessments to Gene Prediction and Phylogenomics. *Mol Biol Evol*.  
665 2018;35(3):543-8.
- 666 83. Steinbiss S, Silva-Franco F, Brunk B, Foth B, Hertz-Fowler C, Berriman M, et al. Companion: a web  
667 server for annotation and analysis of parasite genomes. *Nucleic Acids Res*. 2016;44(W1):W29-34.
- 668

669 **Acknowledgments**

670 This work was funded in part by the European Union’s Horizon 2020 research and innovation  
671 programme under grant agreement 733073 for MultiViVax; the UK Medical Research Council (MRC)  
672 Confidence in Concept Scheme at the University of Oxford [MC\_PC\_16056]; and by the National  
673 Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). The views expressed are  
674 those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.  
675 CMN is a Wellcome Trust Sir Henry Wellcome Postdoctoral Fellow [209200/Z/17/Z]. PJS is the recipient  
676 of a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society  
677 [107668/Z/15/Z]. TAR held a Wellcome Trust Research Training Fellowship [108734/Z/15/Z]. FB is the  
678 recipient of a Wellcome Trust PhD studentship [203764/Z/16/Z]. AK, EA, TDO, AJR and JCR were  
679 supported by the Wellcome Trust [206194/Z/17/Z]. AMB is supported by the MRC [MR/N00227X/1],  
680 Isaac Newton Trust, Alborada Fund, Wellcome Trust ISSF and University of Cambridge JRG Scheme,  
681 GHIT, Rosetrees Trust and the Royal Society. SB and SJD are Jenner Investigators and SJD held a  
682 Wellcome Trust Senior Fellowship [106917/Z/15/Z].

683  
684 The authors are grateful for the assistance of: Julie Furze, Duncan Bellamy, Richard Morter, Catherine  
685 Mair, Lola Matthews, Natalie Lella, Daniel Marshall-Searson, Kathryn Jones and Chris Williams (Jenner  
686 Institute Laboratories and CCVTM, University of Oxford); Richard Tarrant, Eleanor Berrie and Emma  
687 Bolam (Clinical Biomanufacturing Facility, University of Oxford); Julie Staves and the Hematology  
688 Department (Oxford University Hospitals NHS Foundation Trust); Anjali Yadava (WRAIR, USA), Richard  
689 Tedder (Imperial College London, UK) and Nick Day (MORU, Thailand) for clinical advice; Jake Baum  
690 (Imperial College London, UK) for support with mosquito-bite CHMI; Sally Pelling-Deeves and Carly  
691 Banner for arranging contracts (University of Oxford); Karl Hoyle for providing training (Applied Science,  
692 UK); Colin Sutherland (LSHTM, UK), Carole Long (NIAID, NIH, USA) and Chetan Chitnis (Pasteur Institute,  
693 France) for providing reagents; members of the Wellcome Sanger Institute DNA Pipelines team,  
694 particularly Mandy Sanders, Craig Corton and Karen Oliver for their advice and input into the DNA  
695 sequencing process; Chris Jacob, Sonia Goncalves and the MalariaGEN team for support with parasite  
696 genotyping; Wai-Hong Tham, Meta Roostenberg and Susan Barnett for providing scientific advice as part  
697 of the MultiViVax Scientific Advisory Board; and all the study volunteers.

698

699 **Author Contributions**

- 700 • Conceived and performed the experiments: AMM, YT, SES, JRB, AK, DQ, CMN, NJE, TAR, FRL, WR,  
701 KJE, J-SC, TDO, AJR, FB, GML, IDP, AM, MZ, MM, RLR, MB, CHM, JCS, NR, CK, NM, CS, TP, DJR, AMB,  
702 PJS, JS, SB, JCR, SJD.
- 703 • Analyzed the data: AMM, YT, SES, JRB, AK, NJE, KJE, J-SC, EA, TDO, AJR, JCS, MMH, BK, JS, SB, JCR,  
704 SJD.
- 705 • Project Management: AML, FLN, KJJ, IJT.
- 706 • Wrote the paper: AMM, AK, SES, JRB, JCR, SJD.
- 707

708 **Conflict of Interest Statement**

709 The authors declare no conflicts of interest.

710

711 **Data and Materials Availability**

712 Requests for materials should be addressed to the corresponding authors.


713

714 PvW1 genomic assembly and annotation data can be found at:

715 [ftp://ngs.sanger.ac.uk/scratch/project/pathogens/ea10/pvivax/renamed\\_scaffolds/](ftp://ngs.sanger.ac.uk/scratch/project/pathogens/ea10/pvivax/renamed_scaffolds/)



716 **Figures and Legends**




717

718

719 **Figure 1. Safety and parasite growth dynamics of *P. vivax* sporozoite CHMI.**

720 (A) qPCR data for the VAC068 trial. Parasitemia measured in genome copies / mL is shown over time for  
 721 each volunteer. CHMI was initiated by mosquito bite on day 0. Cross symbols indicate the time-point of  
 722 blood donation followed by anti-malarial treatment. Solid lines show qPCR readouts pre-treatment, and

723 dotted lines post-treatment. Solid black line indicates 20 gc/mL (the minimum level to meet positive  
724 reporting criteria); samples below this are shown for information only. **(B)** The solicited systemic adverse  
725 events (AEs) recorded during the CHMI period (from 1 day up until 45 days post-challenge) are shown as  
726 the maximum severity reported by each volunteer and as a percentage of the volunteers reporting each  
727 individual AE (n=2). Color-coding refers to AE grading: 0 = none; 1 = mild; 2 = moderate; 3 = severe. **(C)**  
728 Volunteer temperature (maximum self-recorded by volunteer or measured in clinic) at the indicated  
729 time-points: baseline pre-CHMI; 9 and 11 days post-CHMI (C+9, C+11); time of blood donation; and 1  
730 and 2 days post-treatment (T+1, T+2). AE grading cut-offs are indicated by the dotted lines (yellow =  
731 grade 1; orange = grade 2; red = grade 3). **(D)** Lymphocyte and **(E)** platelet counts plotted as for panel C.  
732 **(F)** The PMR per 48 h was modelled from the qPCR data up until the time-point of blood  
733 donation/treatment; PMR  $\pm$  95% CI is shown for each volunteer. **(H)** Gametocytemia was assessed over  
734 time by qRT-PCR for *pvs25* transcripts; symbols and lines as per panel A.  
735




736

737 **Figure 2. Test of cryopreserved parasite viability by short-term *in vitro* culture assay.**

738 (A) Test vials of cryopreserved parasites from Donor 1 and Donor 2 were thawed and cells used in a  
 739 short-term *in vitro* parasite culture assay. *P. vivax* parasite growth was monitored by qPCR in 20  $\mu$ L  
 740 samples of RBC extracted at the indicated time-points. Median and range of triplicate readings are  
 741 shown in genome copies measured per 20  $\mu$ L sample. (B) Parasite morphology was monitored at the  
 742 same time-points over the first growth cycle by light microscopy of Giemsa-stained thick and thin blood  
 743 films Representative images are shown from Donor 1, and the predominant morphology observed is  
 744 reported.

745



746

747


748 **Figure 3. Parasite growth dynamics of *P. vivax* PvW1 clone blood-stage CHMI.**

749 (A) qPCR data for the VAC069A trial. Parasitemia measured in genome copies (gc) / mL is shown over  
 750 time for each volunteer. CHMI was initiated by blood-stage inoculation on day 0. Cross symbols indicate  
 751 the time-point of diagnosis. Orange = neat inoculum dose; blue = 1:5 and green = 1:20 dilution of the  
 752 neat inoculum dose. Solid black line indicates 20 gc/mL (the minimum level to meet positive reporting  
 753 criteria); samples below this are shown for information only. (B) Kaplan-Meier plot of time to diagnosis  
 754 in days for the VAC069A study. (C) Parasitemia measured in gc/mL at the time-point of diagnosis.

755 Individual data and median are indicated for each dose group. (D) The PMR per 48 h was modelled from

756 the qPCR data up until the time-point of diagnosis; PMR  $\pm$  95% CI is shown for each volunteer. **(E)**  
757 Individual and median PMR are shown with volunteers grouped according to their Duffy blood group  
758 antigen (Fy) serological phenotype. **(F)** Gametocytemia was assessed over time by qRT-PCR for *pvs25*  
759 transcripts; colored lines as per panel A. **(G)** Correlation of total parasitemia measured in gc/mL versus  
760 *pvs25* transcripts/ $\mu$ L. Spearman's rank correlation coefficient and *P* value are shown, n=36.

761




762

763 **Figure 4. Safety analysis of *P. vivax* PvW1 clone blood-stage CHMI.**

764 (A) The solicited systemic adverse events (AEs) recorded during the CHMI period (from 1 day up until 90  
 765 days post-challenge) are shown as the maximum severity reported by each volunteer and as a  
 766 percentage of the volunteers reporting each individual AE (n=6). Color-coding refers to AE grading: 0 =

767 none; 1 = mild; 2 = moderate; 3 = severe. **(B)** The solicited systemic AEs recorded at the indicated time-  
768 points during the CHMI period are shown as the maximum severity reported by each volunteer and as a  
769 percentage of the volunteers reporting each individual AE (n=6). Color-coding as per panel A. 48h-pre =  
770 the 48 hour period prior to *P. vivax* diagnosis; Diagnosis = time-point of diagnosis; +1, +2 and +6 days  
771 post-treatment (T). **(C)** Volunteer temperature (maximum self-recorded by volunteer or measured in  
772 clinic) at the indicated time-points: baseline pre-CHMI; 7 and 14 days post-CHMI (C+7, C+14); time of  
773 diagnosis; and 1 and 6 days post-treatment (T+1, T+6). AE grading cut-offs are indicated by the dotted  
774 lines (yellow = grade 1; orange = grade 2; red = grade 3). **(D)** Lymphocyte and **(E)** platelet counts, and **(F)**  
775 alanine aminotransferase (ALT) measurements, all plotted as for panel C but also including C+28 and  
776 C+90 time-points.

777




778

779 **Figure 5. Induction of serum antibody responses to merozoite antigens during CHMI.**

780 **(A)** Serum anti-PvMSP1<sub>19</sub> IgG ELISA was conducted on samples from the VAC068 mosquito-bite /  
781 sporozoite (spz) CHMI study (n=2) and the VAC069A blood-stage CHMI study (n=5 as one volunteer  
782 withdrew at dC+28). Optical density (OD) 405nm data are shown for sera tested at a 1:100 dilution from  
783 the pre-CHMI (dC-1) and 90 days post-CHMI (dC+90) time-points. Samples color-coded as per previous  
784 figures. **(B)** Serum anti-PvDBP\_RII (Sall allele) IgG as measured by standardized ELISA, reporting in  
785 arbitrary units (AU). Same samples tested as in panel A. Vaccine = positive control samples (n=8) from a  
786 previous Phase Ia clinical trial of a PvDBP\_RII vaccine (29). Individual data and median are shown.

787





788

789 **Figure 6. Cluster analysis of the PvW1 vivax interspersed repeat (VIR) proteins.**

790 Cluster analysis of the 1145 predicted VIR proteins encoded by the PvW1 genome compared to those of  
791 other *P. vivax* isolates (30, 31). Each spot represents a VIR protein from either PvW1 (orange), PvC01  
792 (green), PvT01 (pink), PvSall (black) and PvP01 (blue). Relatedness between the proteins is represented  
793 by distance, therefore more closely related proteins cluster together. Most of the clusters contain  
794 proteins from several isolates suggesting that the clusters are not restricted to specific genomes or  
795 geographical distribution.

796 **Table**

797

Genome Features	PvW1	PvP01	PvC01	PvT01	Sall
<b>Nuclear genome</b>					
Assembly size (Mb)	28.9	29	30.2	28.9	26.8
G + C content (%)	39.9	39.8	39.2	39.7	42.3
No. scaffolds assigned to chrom.	14	14	14	14	30
No. unassigned scaffolds	3	226	529	359	2745
No. genes	6583	6642	6690	6464	5433
No. pir (VIR) genes	1145	1212	1061	867	346
<b>Mitochondrial genome</b>					
Assembly size (bp)	5994	5989	-	-	5990
G + C content (%)	30.5	30.5	-	-	30.5
<b>Apicoplast genome</b>					
Assembly size (kb)	34.5	29.6	27.6	6.6	5.1
G + C content (%)	14.4	13.3	12.7	19.7	17.1
No. genes	54	30	3	0	0

798

799 **Table 1. Comparison of genome assembly statistics between PvW1 and other *P. vivax***  
 800 **assemblies.**

801 PvW1 genome assembly statistics were compared with the best available existing assemblies: PvP01,

802 PvC01, PvT01 and Sall (30, 31). pir = *P. vivax* Plasmodium interspersed repeat, also known as VIR.

803 **Methods**

804

805 **Thailand: Source patient case-finding and preparation of infected mosquitoes**

806 For infection of mosquitoes, source patients were recruited from a medical clinic in Songkhala, one of  
807 Thailand's southern *Plasmodium vivax* endemic areas; this protocol was approved by the Ethical  
808 Committee of The Faculty of Tropical Medicine, Mahidol University, Thailand (protocol number TMEC  
809 18-014). Patients were consented to having a 20 mL blood sample taken for blood-borne infection  
810 testing, endemic mosquito-borne infection testing and *P. vivax* diagnostic testing. *P. vivax* was first  
811 diagnosed by microscopy at the field site, then confirmed by microscopy and nested PCR analysis  
812 following transport of the blood samples to the Mahidol Vivax Research Unit (MVRU), Mahidol  
813 University, Bangkok, to rule out the presence of any other *Plasmodium* species (data not shown). As  
814 *Anopheles* species are also known vectors of *Wucherichia bancrofti*, the main causative agent of  
815 lymphatic filariasis, source patient blood was also screened for filarial disease via rapid diagnostic test  
816 for IgG4 antibodies to the *W. bancrofti* Wb123 antigen (Standard Diagnostics, Inc.); all tests were  
817 negative.

818

819 Approximately 5 mL of each 20 mL blood sample was used to feed up to 3000 laboratory-bred  
820 *Anopheles dirus* mosquitoes via a direct membrane feeding system at MVRU. These mosquitoes were  
821 previously reared in the laboratory and fed only on rigorously screened human blood (purchased from  
822 the Red Cross) to maintain the colony and induce egg-laying. Mosquito infectivity was confirmed at 6-7  
823 days post-feeding via oocyst counts following dissection of the midgut from representative mosquitoes.

824 In parallel to the mosquito-feeding, and in real-time, the remaining ~15 mL of the source patients'  
825 serum and whole blood samples were shipped from Thailand to the UK. These underwent additional  
826 testing for blood-borne infections and mosquito-borne diseases other than malaria. For maximal  
827 assurance of safety, serological tests for human immunodeficiency virus-1 (HIV-1) and HIV-2, human T  
828 cell lymphotropic virus-1 (HTLV-1) and HTLV-2, hepatitis B and C and syphilis were performed at Oxford  
829 University Hospitals NHS Trust, Oxford, UK. Alongside these, whole blood from the source patients were  
830 also screened for Japanese B encephalitis virus and chikungunya virus by PCR at the Rare Imported  
831 Pathogens Laboratory (RIPL) in the UK, due to anecdotal reports of both arboviral infections in  
832 *Anopheles* species (64) and in line with the protocols followed by WRAIR in their previous *P. vivax* CHMI  
833 study (12). Finally, as a further precautionary measure, although *Anopheles* species are not known to be

834 vectors of dengue, Zika or West Nile viruses, PCR for these infections were also performed at RIPL on the  
835 source patients' blood samples. All source patient infection screen tests were negative.

836 Alongside infection testing, molecular speciation of *P. vivax* was re-confirmed for each sample by nested  
837 PCR using whole blood and an in-house research-grade laboratory assay method, adapted from (65), at  
838 the University of Oxford. Positive control DNA samples for different *Plasmodium* parasite species were a  
839 kind gift from Prof Colin Sutherland (LSHTM, UK). Each sample was also genotyped to measure  
840 multiplicity of *P. vivax* infection; here extracted DNA was processed by the Wellcome Sanger Institute in  
841 Cambridge, UK using a SNP barcode panel as described by the MalariaGEN network (66), with detailed  
842 methods available at <https://www.malariagen.net/resource/29>.

843 The batch of mosquitoes fed off blood from patient C05-001 was ultimately selected for use in the  
844 VAC068 CHMI trial, and was shipped from MVRU in Thailand to Imperial College London, UK. Shipment  
845 took less than 48 hours, and no mosquito mortality was observed.

#### 846 **VAC068: Study approvals**

847 VAC068 was a clinical study to assess the safety of controlled human *P. vivax* malaria infection through  
848 experimental sporozoite inoculation (by mosquito-bite) of healthy malaria-naïve UK adults, and to  
849 characterize parasite growth and immune responses. The study was conducted in the UK at the Centre  
850 for Clinical Vaccinology and Tropical Medicine (CCVTM), University of Oxford (follow-up post-CHMI,  
851 admission for blood donation and treatment) and at the Sir Alexander Fleming Building (Infection and  
852 Immunity section) Imperial College of Science, Technology and Medicine, London (sporozoite challenge  
853 of volunteers). Recruited volunteers were healthy, malaria-naïve adults (male and female) aged  
854 between 18 and 50 years. The trial was registered on ClinicalTrials.gov (NCT03377296) and was  
855 conducted according to the principles of the current revision of the Declaration of Helsinki 2008 and in  
856 full conformity with the ICH guidelines for Good Clinical Practice (GCP). All volunteers signed written  
857 consent forms, and consent was checked to ensure volunteers were willing to proceed prior to CHMI.  
858 The study received ethical approval from the UK NHS Research Ethics Service (Oxfordshire Research  
859 Ethics Committee A, Ref 17/SC/0389).

860

861 GCP compliance was independently monitored by the University of Oxford Clinical Trials and Research  
862 Governance (CTRG) Office. An independent local safety monitor and safety monitoring committee acted  
863 as independent experts, who, if required, could evaluate any adverse events and advise the  
864 Investigators on treating or referring a volunteer to secondary care.

865 The primary objectives of the trial were i) to assess the safety and feasibility of *P. vivax* sporozoite CHMI  
866 (via mosquito-bite) in two healthy human volunteers; ii) to assess the immune response to primary *P.*  
867 *vivax* infection delivered by mosquito bite; and iii) to assess gametocytemia following primary *P. vivax*  
868 infection delivered by mosquito bite. Secondary objectives were to obtain up to 250 mL of blood from  
869 each infected volunteer and produce a cryopreserved stabilate of parasite-infected human red blood  
870 cells (iRBC) for future use in blood-stage *P. vivax* CHMI studies.

#### 871 **VAC068: Specific considerations for screening of healthy UK adult volunteers**

872 Two healthy UK adult volunteers were consented and enrolled into the VAC068 trial. Alongside the  
873 routine screening and inclusion/exclusion criteria used for CHMI trials at the University of Oxford site  
874 (see below), these volunteers were also specifically screened to be: i) blood group O rhesus-negative (O-  
875 ), i.e. universal donors suitable for production of the cryopreserved iRBC stabilate; ii) Duffy-blood group  
876 positive, to ensure successful *P. vivax* blood-stage infection (7, 25); iii) glucose-6-phosphate  
877 dehydrogenase (G6PD) normal, to ensure no hemolytic anemia following curative treatment with  
878 primaquine (26); iv) cytochrome P450 2D6 (CYP2D6) genotype predicted to be an extensive metabolizer  
879 phenotype (27), to minimize chance of primaquine drug treatment failure against hypnozoites (13), and  
880 v) able to satisfactorily metabolize primaquine after administration of a 30 mg test dose (13).

881 Blood group (ABO, Rhesus and Duffy) were characterized and G6PD activity levels were measured in the  
882 NHS Hematology Laboratory at Oxford University Hospitals NHS Trust, UK. CYP2D6 genotype testing was  
883 performed by PharmGenomics GmbH, Germany, using the GenoChip method and NCBI reference  
884 sequence NG\_008376.3. Classification was done according to (27). Measurement of the  
885 pharmacokinetic parameters of primaquine was performed by the Division of Experimental  
886 Therapeutics, Drug Metabolism and Disposition, at the Walter Reed Army Institute of Research, USA.  
887 Plasma samples from both volunteers, taken from 0 to 24 h after a single dose of primaquine (PQ), were  
888 analyzed by Liquid Chromatography-Mass Spectrometry (LC-MS) for levels of PQ and its major  
889 metabolite, carboxyprimaquine (cPQ). All plasma samples were frozen at -80 °C in laboratory facilities

890 until ready for analysis. Calibration and quality control samples were prepared by spiking blank human  
891 plasma with the analyte of interest. Calibration, quality control, and study samples were extracted using  
892 a 2x volume of acetonitrile containing an internal standard (mefloquine, MQ). The ratio of the peak area  
893 of the analyte to the peak area of the internal standard was used for calibration and interpolation of  
894 sample concentrations. LC-MS methodology has been previously described in detail (13, 67).

895 Each volunteer also underwent an extensive screen for blood-borne infections, performed in line with  
896 the Joint UK Blood Transfusion and Tissue Transplantation Services Professional Advisory Committee  
897 guidelines (68), in the microbiology laboratory at OUH NHS Trust. Testing comprised serological tests for  
898 HIV-1 and HIV-2, hepatitis B and C, syphilis (anti-treponemal antibody), and HTLV-1 and HTLV-2 at  
899 screening; and nucleic acid amplification tests for HIV-1 and hepatitis B and C, as well as repeat  
900 serological tests for HTLV-1 and HTLV-2 and syphilis 7 days before challenge. In addition, the volunteers  
901 were screened serologically for Epstein-Barr virus (EBV) and cytomegalovirus (CMV). However, given i)  
902 both of these viruses are cell-associated, being carried within leukocytes, and the risk of transfusion-  
903 induced CMV and EBV infection has been deemed to be minimal following leukodepletion (69); and ii)  
904 the historical experience of us and others with a *P. falciparum* 3D7 clone blood-stage inoculum that  
905 originated from a CMV and EBV seropositive donor (15, 16), we did not exclude volunteers based on  
906 their serostatus for these two viruses.

#### 907 **VAC068: Other routine screening, and full list of inclusion and exclusion criteria**

908 For the two VAC068 volunteers, a medical history and physical examination were conducted at the  
909 screening visit. Hematology screening bloods included a full blood count, and a hemoglobinopathy  
910 screen was performed retrospectively post-challenge; whilst biochemistry measurements at screening  
911 included urea and electrolytes, liver function tests, magnesium & cholesterol. Dipstick urinalysis for all  
912 volunteers and pregnancy testing for female volunteers were conducted at screening, as well as an  
913 electrocardiogram. Pregnancy testing (in the form of serum beta human chorionic gonadotrophin,  
914 BHCG) was also carried out in female volunteers the day before CHMI (dC-1), and then at 7 days post-  
915 CHMI (dC+7), dC+14, just prior to starting primaquine treatment and at dC+21. The full list of inclusion  
916 and exclusion criteria is shown below:

917 **Inclusion criteria:** Volunteers had to satisfy all the following criteria to be eligible for the study:

- 918 • Healthy adult aged 18 to 50 years.
- 919 • Blood group O, Rhesus negative.
- 920 • Red blood cells positive for the Duffy antigen/chemokine receptor (DARC).
- 921 • High metabolizer of primaquine (as determined by CYP2D6 genotype).
- 922 • Normal serum levels of glucose-6-phosphate dehydrogenase (G6PD).
- 923 • Satisfactory serum levels of primaquine (when administered as test dose).
- 924 • Able and willing (in the Investigator's opinion) to comply with all study requirements.
- 925 • Willing to allow the Investigators to discuss the volunteer's medical history with their General  
926 Practitioner.
- 927 • Women only: Must practice continuous effective contraception for the duration of the clinic  
928 visits (first 3 months post-CHMI).
- 929 • Agreement to refrain from blood donation during the course of the study and for at least 5 years  
930 after the end of their involvement in the study.
- 931 • Written informed consent to participate in the trial.
- 932 • Reachable (24/7) by mobile phone during the period between CHMI and completion of all  
933 antimalarial treatment.
- 934 • Willing to take a curative anti-malaria regimen following CHMI.
- 935 • Willing to be admitted to the research bay at the CCVTM on the Churchill Hospital, Oxford site  
936 for blood donation and clinical monitoring, until antimalarial treatment is underway and their  
937 symptoms are settling.

938 • Willing to reside in Oxford for the duration of the study, until all antimalarials have been  
939 completed.

940 • Answer all questions on the informed consent quiz correctly.

#### 941 **Exclusion Criteria**

942 Volunteers were not eligible to participate if any of the following applied:

943 • History of clinical malaria (any species).

944 • Travel to a clearly malaria endemic locality during the study period or within the preceding six  
945 months.

946 • Use of systemic antibiotics with known antimalarial activity within 30 days of CHMI (e.g.  
947 trimethoprim-sulfamethoxazole, doxycycline, tetracycline, clindamycin, erythromycin,  
948 fluoroquinolones and azithromycin).

949 • Blood group A/B and/or Rhesus positive.

950 • Red blood cells negative for the Duffy antigen/chemokine receptor (DARC).

951 • Glucose-6-phosphate dehydrogenase (G6PD) deficient.

952 • Inadequate serum levels of primaquine (when administered as test dose).

953 • Current anemia (hemoglobin < 9 g/dL).

954 • Use of immunoglobulins or blood products (e.g., blood transfusion) at any time in the past.

955 • History of sickle cell anemia, sickle cell trait, thalassemia or thalassemia trait or any  
956 hematological condition that could affect susceptibility to malaria infection.

957 • Venepuncture unlikely to allow a 250 mL blood donation (as determined by the Investigator).



- 958 • Receipt of an investigational product in the 30 days preceding enrolment, or planned receipt  
959 during the study period.
- 960 • Prior receipt of an investigational vaccine likely to impact on interpretation of the trial data or  
961 the *P. vivax* parasite as assessed by the Investigator.
- 962 • Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV  
963 infection; asplenia; recurrent, severe infections and chronic (more than 14 days)  
964 immunosuppressant medication within the past 6 months (inhaled and topical steroids are  
965 allowed).
- 966 • History of allergic disease or reactions likely to be exacerbated by malaria infection.
- 967 • Pregnancy, lactation or intention to become pregnant during the study.
- 968 • Use of medications known to cause prolongation of the QT interval **and** existing contraindication  
969 to the use of Malarone.
- 970 • Use of medications known to have a potentially clinically significant interaction with Riamet®  
971 **and** Malarone.
- 972 • Any clinical condition known to prolong the QT interval.
- 973 • History of cardiac arrhythmia, including clinically relevant bradycardia.
- 974 • Disturbances of electrolyte balance, e.g. hypokalemia or hypomagnesemia.
- 975 • Family history of congenital QT prolongation or sudden death.
- 976 • Contraindications to the use of both of the proposed anti-malarial medications; Riamet®  
977 Malarone.
- 978 • Contraindications to the use of primaquine.
- 979 • History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ).

- 980       • History of serious psychiatric condition that may affect participation in the study.
- 981       • Any other serious chronic illness requiring hospital specialist supervision.
- 982       • Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 42  
983       standard UK units every week.
- 984       • Suspected or known injecting drug abuse in the 5 years preceding enrolment.
- 985       • Hepatitis B surface antigen (HBsAg) detected in serum.
- 986       • Seropositive for HTLV-1 or -2 (antibodies to HTLV) at screening or at dC-7.
- 987       • Seropositive for hepatitis C virus (antibodies to HCV) at screening or at dC-7 (**unless** has taken  
988       part in a prior hepatitis C vaccine study with confirmed negative HCV antibodies prior to  
989       participation in that study, and negative HCV RNA PCR at screening for this study).
- 990       • Seropositive for RPR (antibodies to syphilis) at screening or at dC-7.
- 991       • Detectable HIV or hepatitis C virus by PCR at dC-7.
- 992       • Positive family history in both 1<sup>st</sup> AND 2<sup>nd</sup> degree relatives < 50 years old for cardiac disease.
- 993       • Volunteers unable to be closely followed for social, geographic or psychological reasons.
- 994       • Any clinically significant abnormal finding on biochemistry or hematology blood tests, urinalysis  
995       or clinical examination. In the event of abnormal test results, confirmatory repeat tests will be  
996       requested.
- 997       • Any other significant disease, disorder, or finding which may significantly increase the risk to the  
998       volunteer because of participation in the study, affect the ability of the volunteer to participate  
999       in the study or impair interpretation of the study data.

1000

1001 **VAC068: Mosquito-bite CHMI at Imperial College, London**

1002 Sporozoite CHMI delivered by mosquito-bite was conducted in the designated category 3 (CL3) suite  
1003 within the Sir Alexander Fleming Building (SAF) at Imperial College London, UK. Mosquitoes were  
1004 supplied directly from Thailand via World Courier in a temperature-controlled box at 28 °C with receipt  
1005 acknowledged by an appropriate researcher. Infected mosquitoes were immediately transferred to a  
1006 secure room within the insectary and maintained on 10 % fructose until 24 hours prior to skin feeding.  
1007 Prior to CHMI, an appropriately trained researcher prepared the mosquitoes into secure small pots that  
1008 were brought to the volunteers as described in a Standard Operating Procedure (SOP). The two healthy  
1009 UK adult volunteers screened and consented to take part in VAC068 were each exposed to five  
1010 “infectious bites” under controlled conditions. Here, an infectious mosquito bite was defined post-skin  
1011 feeding by microscopic examination, with confirmation of >10 sporozoites in the mosquito’s salivary  
1012 glands as well as the presence of human blood in the midgut.

1013

1014 **VAC068: Participant follow-up post-CHMI**

1015 The two VAC068 volunteers were reviewed by telephone daily for the first 5 days post-CHMI (dC+1 to  
1016 dC+5), then reviewed in clinic on the evening of day 6 post-CHMI (dC+6.5) and subsequently twice daily  
1017 (morning/evening) to monitor for symptoms/signs of malaria and check for development of parasitemia  
1018 by quantitative PCR (qPCR) and thick blood film microscopy.

1019 Volunteers were admitted to the clinical trial unit at the CCVTM in Oxford according to a clinical /  
1020 diagnostic algorithm. This stipulated admission at an absolute threshold parasitemia of >10,000 gc/mL  
1021 OR at threshold of >2,000 gc/mL in the presence of significant malaria symptoms. Following admission,  
1022 the protocol allowed for a 72 hour window in which to donate blood; volunteer 01-008 donated blood  
1023 first at dC+14 and volunteer 01-004 at dC+14.5. A 250 mL blood sample was collected using aseptic  
1024 technique, via a whole blood donation kit containing an in-line leukodepletion filter (Leukotrap WB,  
1025 Haemonetics Corp), at room temperature. The blood donation kit was placed on an agitator (Blood  
1026 Collection Monitor and Mixer, HemoFlow 400™, Applied Science UK Ltd). This maintained automatic  
1027 mixing of the blood during flow at a rate of >30mL/min, ensuring combination with the contained  
1028 anticoagulant and so minimizing the risk of coagulation. In order to anonymize the blood donor, these  
1029 samples were randomized and relabelled either “Donor 1” or “Donor 2”. Traceability of the blood donor

1030 is, however, maintained within a confidential clinical record which may be accessed by the trial Chief  
1031 Investigator on behalf of the trial Sponsor if deemed necessary for safety reasons.

1032 Antimalarial treatment (60-hour course of artemether/lumefantrine, Riamet®) was started immediately  
1033 after blood donation, followed by a 14-day course of primaquine, 30 mg once daily. Both volunteers  
1034 attended clinic on alternate mornings for directly observed primaquine treatment (telephoned to  
1035 confirm consumption on intervening days) until they had completed the course.

1036 Final follow-ups in clinic were performed at dC+45 and at dC+90, and between these days volunteers  
1037 were contacted fortnightly by email (on dC+59 and dC+73) to ensure they remained well and  
1038 asymptomatic. Both volunteers also underwent repeat serological testing for HIV-1, HIV-2, hepatitis B  
1039 and C, syphilis, HTLV-1 and HTLV-2 at dC+90 to ensure that no seroconversion from a recently-acquired  
1040 infection (that may have been undetectable around the time of CHMI) had occurred since the challenge  
1041 period. Subsequently the volunteers received an email from the Investigators fortnightly up until one  
1042 year post-CHMI and then annually from 1-5 years post-CHMI (ongoing). This was to enquire about the  
1043 presence of any symptoms suggestive of *P. vivax* malaria relapse (or any medical intervention  
1044 sought/received) since they were last seen.

#### 1045 **Total parasite quantification**

1046 Quantitative PCR (qPCR) was used to monitor total *P. vivax* blood-stage parasitemia in volunteers' blood  
1047 in real-time. The assay targets the 18S ribosomal RNA (rRNA) gene and was adapted from previously  
1048 published methodology (19, 53). DNA was initially extracted from 0.4 mL whole EDTA blood using the  
1049 Qiagen DSP DNA Blood mini Kit. 5 % of each extraction (total eluate volume = 100 µL, with 5 µL used per  
1050 assay) was run in triplicate for qPCR; equivalent to 60 µL blood directly assessed. An additional  
1051 extraction was performed post-CHMI on aliquots of frozen blood from all time-points, using a  
1052 QIASymphony SP robot, utilizing the Qiagen DSP Blood Midi Kit and the pre-loaded Blood 400 v6  
1053 extraction protocol, with a 100 µL elution in ATE buffer selected, (giving identical extraction and elution  
1054 volumes in both manual and automated extractions). Both methods had been shown to be equivalent,  
1055 but with greater ease of use and reduced chance of cross contamination with the automated extraction.  
1056 Additionally, aliquots of dC-1 samples were spiked with a known concentration of positive control DNA  
1057 to check there was no presence of PCR inhibitors in volunteers' blood prior to CHMI.

1058 Following DNA extraction, a standard Taqman absolute quantitation was used against a standard curve  
1059 to amplify a 183 bp PCR product from the multi-copy, highly conserved 18S ribosomal RNA genes of  
1060 *Plasmodium* spp. qPCR using the following adapted oligonucleotide primers and probe (19): 18s forward  
1061 primer 5'-AGG AAG TTT AAG GCA ACA ACA GGT-3', 18s reverse primer 5'-GCA ATA ATC TAT CCC CAT  
1062 CAC GA-3' and shortened FAM labelled probe sequence 5'-TGA ACT AGG CTG CAC GCG-3', was run on an  
1063 ABI StepOne Plus machine with v2.3 software. Default Universal qPCR (target FAM-NFQ-MGB) and QC  
1064 settings were used apart from the use of 40 cycles and 25  $\mu$ L reaction volume.

1065 This qPCR detects DNA from pan-*Plasmodium* species, but unlike the synchronous growth of *P.*  
1066 *falciparum*, circulating *P. vivax* iRBC may contain up to 10-15 individual genomes (in blood-stage late  
1067 trophozoites and schizonts) and can also include the presence of gametocytes. The qPCR score is  
1068 therefore reported in genome copies/mL (gc/mL) as opposed to a quantity of parasites.

1069 The standard curve was generated from dilution of a linearized plasmid encoding part of the  
1070 *Plasmodium* spp. 18S ribosomal RNA gene and calibrated using known *P. falciparum* spiked blood  
1071 samples initially and then reference DNA extracted from whole blood from *P. vivax*-infected patient  
1072 samples in Thailand where parasites had been quantified by microscopy (kindly provided by Mahidol  
1073 University). Based upon earlier results obtained using dilution series of microscopically-counted cultured  
1074 *P. falciparum* (Pf) parasites, a Pf-specific 18S rRNA Taqman qPCR showed a lower limit of quantification  
1075 (LLQ, defined as %CV <20%) of around 20 Pf parasites (p)/mL blood (28). Counted parasite dilution series  
1076 results also suggested that the lower limit of probable detection (LLD, i.e. a probability of >50% of  $\geq 1$   
1077 positive result among three replicate qPCR reactions) is in the region of 5 p/mL, while samples at 1 p/mL  
1078 are consistently negative (24/24 qPCR reactions). Positive results in this assay (even at very low level)  
1079 are thus essentially 100 % specific for genuine parasitemia, with positive results beneath the LLQ likely  
1080 to signify parasitemia in the range 2-20 p/mL. Similar sensitivity in terms of genome copy detection was  
1081 observed when using the pan-*Plasmodium* qPCR described above and the diluted *P. vivax*-infected  
1082 patient blood test samples from Thailand. As noted, these samples had microscopically mixed life stages  
1083 with varying copies of the 18S rRNA gene and thus the assay readout is reported in terms of gc/mL.  
1084 Based on this and the above experiments, 20 gc/mL was set as the minimum level to meet positive  
1085 reporting criteria, but all raw data are shown in the Results.

1086 For quality control purposes, qPCR samples were re-tested if;

- 1087       • Replicates included a mixture of positive and negative (in terms of amplification) results with  
1088           one or more positive results > 100 gc/mL;  
1089       • The % CV of any results were high outliers.

1090 All 'passed' data following the quality control steps above, including any 0 values, were used to generate  
1091 the final mean qPCR result for each time-point.

### 1092 **Thick blood film microscopy**

1093 Collection of blood, preparation of thick films and slide reading were performed according to Jenner  
1094 Institute Standard Operating Procedure (SOP) ML009. Briefly, slides were prepared using Field's stain A  
1095 and then Field's stain B. 200 fields at high power (1000x) were read. Visualization of 2 or more parasites  
1096 in 200 high power fields constituted a positive result. For internal quality control, all slides were read  
1097 separately by two experienced Thai microscopists, with a third read if results were discordant.

### 1098 **VAC068: Cryopreservation and *in vitro* testing of *P. vivax* infected blood**

1099 After blood donation, the leukodepleted blood from both volunteers was maintained at ~37 °C and  
1100 transported immediately to the Jenner Institute Laboratories, University of Oxford. Here, RBC were  
1101 separated from plasma by centrifugation before mixing the RBC with Glycerolyte 57 (Fenwal 4A7833) at  
1102 1:2 volume ratio. All procedures were conducted according to SOPs under stringent Quality Assurance  
1103 (QA) oversight and guidance from a Qualified Person (QP) at the University of Oxford. The RBC-  
1104 Glycerolyte mixture was finally aliquoted at 1.5 mL per cryovial, transferred into CoolCells (Corning  
1105 432009) and placed at -80 °C within 2 h 30 min of blood donation to freeze overnight; the following day  
1106 the frozen cryovials were transferred to long-term storage in liquid nitrogen.

1107 A final screen for blood-borne infections was conducted on the plasma, derived directly from the blood  
1108 donation (separated from the RBC prior to cryopreservation), in line with testing procedures performed  
1109 by the UK NHS Blood Transfusion service. RNA PCR for HIV-1 and hepatitis C, DNA PCR for hepatitis B,  
1110 EBV CMV, and serology for HIV-2, HTLV-1, HTLV-2, and *Treponema pallidum* was performed on thawed  
1111 plasma samples at University Hospitals Birmingham NHS Foundation Trust, UK (Public Health England,  
1112 Birmingham Laboratory). Separately, screening of a blood sample from Donor 1 for the Kell blood group  
1113 antigen was performed by Oxford University Hospitals NHS Trust Haematology Laboratory, UK.

1114 The cryopreserved stabilate from Donor 1 was also tested for sterility by direct inoculation and  
1115 mycoplasma by specific culture; both tests were negative. In addition, endotoxin was quantified by  
1116 kinetic chromogenic limulus amoebocyte lysate assay, reporting a result <2 EU/mL. These assays were  
1117 conducted by a Contract Research Organization: SGS Vitrology, Glasgow, UK or SGS Vitrology's  
1118 contracted services at Moredun Scientific, Penicuik, Scotland, UK. The tests were non-regulatory  
1119 standard and performed for information only.

#### 1120 **Parasite viability assay**

1121 A vial of the cryopreserved stabilate was gently warmed at 37 °C, before addition of 0.2x volume 12 %  
1122 NaCl dropwise. After 5 min incubation, the cells were pelleted at 1500 xg for 5 min. Supernatant was  
1123 removed, before addition of 10x volume 1.6 % NaCl dropwise followed by 10x volume 0.9 % NaCl. The  
1124 cells were then immediately spun down as before and the pelleted RBC transferred to short term *in vitro*  
1125 culture. Here, the sample was added to McCoy 5A medium (Sigma) supplemented with 2.4 g/L D-  
1126 glucose, 25 mM HEPES and 200 mM hypoxanthine (all from Sigma, St. Louis) and 20 % heat-inactivated  
1127 human O serum, in an atmosphere of 5 % O<sub>2</sub> at 37.5 °C. At each time point, a 20 µL aliquot of RBC was  
1128 taken for DNA extraction and parasite genome copies quantified by qPCR. In addition, 10 µL RBC were  
1129 used to make thick and thin blood smears for parasite growth and morphology monitoring by light  
1130 microscopy. Here, Giemsa stain (Sigma, St. Louis) was filtered using a 0.8 µm filter (Merck Millipore,  
1131 Ireland) then diluted to 5 % using water, prior to staining the slides at RT for 20 min before gently  
1132 washing and drying the slides

#### 1133 **VAC069: Study approvals**

1134 The subsequent VAC069 trial assessed the safety and feasibility of blood-stage *P. vivax* CHMI through  
1135 experimental inoculation with the cryopreserved PvW1 infected erythrocytes (collected in VAC068) in  
1136 healthy malaria-naïve UK adults. The VAC069 trial is an on-going multi-part study, and the work reported  
1137 here covers the first part of this trial in six volunteers (termed "VAC069A"). All six volunteers were  
1138 challenged and followed up at the CCVTM, Oxford, UK. The trial was registered on ClinicalTrials.gov  
1139 (NCT03797989) and was conducted according to the principles of the current revision of the Declaration  
1140 of Helsinki 2008 and in full conformity with the ICH guidelines for GCP. All volunteers signed written  
1141 consent forms, and consent was checked to ensure volunteers were willing to proceed prior to CHMI.  
1142 The study received ethical approval from the UK NHS Research Ethics Service (South Central –

1143 Hampshire A Research Ethics Committee), Ref 18/SC/0577. Independent safety monitoring and GCP  
1144 compliance was monitored as for VAC068.

1145 The VAC069A trial tested safety and infectivity of the PvW1 cryopreserved stabilate (from Donor 1 in  
1146 VAC068) by blood-stage CHMI, in line with prior experience using the *P. falciparum* blood-stage CHMI  
1147 model (14-16). This proof-of-concept clinical trial sought to assess feasibility of infection at three  
1148 different doses of PvW1 blood-stage inoculum. Two volunteers receive a whole vial's worth of iRBC  
1149 ("neat"), two volunteers received one fifth of the challenge dose via a 1:5 dilution, and the final two  
1150 volunteers were inoculated with one twentieth of the dose via a 1:20 dilution.

### 1151 **VAC069A: Study population and screening**

1152 This study recruited healthy, malaria-naïve adult volunteers (male and female) aged between 18 and 50  
1153 years. The inclusion and exclusion criteria for the VAC069A study were very similar to those of VAC068,  
1154 with the only differences being removal of criteria related to ABO/Rhesus blood group, G6PD activity,  
1155 CYP2D6 genotype and primaquine metabolism (as not relevant to blood-stage CHMI) and removal of  
1156 viral serology at dC-7 (as these volunteers were not donating blood for use in future clinical studies).  
1157 Duffy blood group positivity (and serological phenotype) was also confirmed. Screening hemoglobin cut-  
1158 offs were also more conservative (Hemoglobin <120 g/L for a female volunteer or <130 g/L for a male  
1159 volunteer prior to primary CHMI) to minimize the chances of anemia resulting from cumulative blood  
1160 volume taken over the whole VAC069 trial period.

### 1161 **VAC069A: Blood-stage inoculum preparation and CHMI**

1162 The PvW1 blood-stage inoculum was thawed and prepared under strict aseptic conditions as previously  
1163 described for *P. falciparum* (16), with some modifications. Briefly, five vials of cryopreserved  
1164 erythrocytes (containing approximately 0.5mL of red blood cells each) were thawed in parallel in a  
1165 derogated containment level III laboratory area using solutions licensed for clinical use and single-use  
1166 disposable consumables. A class II microbiological safety cabinet (MSC) was used to prepare the  
1167 inoculum, which was fumigated with hydrogen peroxide and decontamination validated prior to use. To  
1168 prepare the inoculum, 0.2 volume 12 % saline was added dropwise to the contents of each (~1.5 mL) vial  
1169 of thawed infected blood. Each sample was left for 5 min, before an additional 10 volumes of 1.6 %  
1170 saline was added dropwise prior to centrifugation for 4 min at 800 xg. Each supernatant was removed,



1171 and 10 mL of 0.9% saline was added dropwise. The cell pellets were then washed twice in 0.9 % saline  
1172 before a final resuspension in 0.9 % saline. At this final step, the five samples (from the five original  
1173 cryovials) were combined into one 10 mL sample in 0.9 % saline. This 10 mL suspension was then divided  
1174 into aliquots, equivalent to one original cryovial (i.e. 2mL), one fifth of a cryovial, and one twentieth of a  
1175 cryovial by further dilution in 0.9 % saline. Each dosing aliquot was made up to a total volume of 5 mL in  
1176 0.9 % saline in a sterile syringe for injection and transported to the clinic. Retrospective qPCR analysis  
1177 indicated the neat inoculum dose to contain 2322 gc in total (although this is likely to contain a mixture  
1178 of live and dead parasites post-thawing).

1179 The reconstituted blood-stage inoculum (5 mL per syringe) was injected intravenously via an indwelling  
1180 cannula, preceded and followed by a saline flush. Single volunteers from each of the three dosing groups  
1181 were administered the inoculum first. The inoculum was subsequently administered to the remaining  
1182 three volunteers (one from each dosing group). All six volunteers were inoculated within 2 h 24 min of  
1183 thawing the cryopreserved stabilate. Volunteers were then observed for 1 h before discharge from the  
1184 clinical facility. Following CHMI, a leftover sample of the inoculum was also cultured and shown to be  
1185 negative for bacterial contamination.

#### 1186 **VAC069A: Participant follow-up post-CHMI**

1187 The VAC069A volunteers were reviewed in clinic once in the morning of day 1 post-CHMI (dC+1), then  
1188 twice daily from day 2 until day 12 post-CHMI inclusive (dC+2 to dC+12.5). From dC+13 to dC+20.5, visits  
1189 were either once or twice daily depending on the qPCR result. Once a qPCR threshold of 1000 gc/mL was  
1190 reached, visits continued twice daily. If qPCR had not reached this threshold, visits reduced to once  
1191 daily. Diagnostic criteria were based on thick blood film microscopy results and qPCR in the presence or  
1192 absence of symptoms:

- 1193 • If symptomatic:  $\geq 2$  parasites visible on 200 fields (thick blood film microscopy) OR a parasitemia  
1194 of  $>5,000$  gc/mL by qPCR.
- 1195 • If asymptomatic: a parasitemia of  $>10,000$  gc/mL on qPCR OR a parasitemia of  $>5,000$  gc/mL  
1196 PLUS  $\geq 2$  parasites visible on 200 fields (thick blood film microscopy).

1197

1198 Treatment was completed with either a 60-hour course of Riamet® or a 48-hour course of Malarone.  
1199 Volunteers were directly observed taking their 24- and 48-hour doses (T+1 and T+2 visits, respectively).  
1200 Subsequent follow-up visits in clinic were 6 days post-initiation of antimalarial treatment (T+6), 28 days,  
1201 45 days and 90 days post-CHMI.

## 1202 **VAC068 and VAC069A safety analysis**

1203 Data on both solicited AEs occurring during and after the CHMI period (that may have related to CHMI  
1204 or antimalarial treatment) as well as any unsolicited AEs, were collected at clinic visits, from dC+1 up  
1205 until the end of primaquine antimalarial treatment (VAC068) and until 6 days post-initiation of  
1206 Riamet®/Malarone treatment (VAC069A). Volunteers were given a card on which to document the end  
1207 date of any outstanding malaria symptoms on-going between completing anti-malarial therapy and their  
1208 next clinic visit (dC+45 in VAC068, and dC+28 in VAC069A).

1209 Data on serious adverse events (SAEs) were collected throughout the entire study period (5 years for  
1210 VAC068, 3 months for VAC069A).

1211 Volunteers graded all AEs as mild, moderate or severe:

- 1212 • **GRADE 0:** None.
- 1213 • **GRADE 1:** Transient or mild discomfort (< 48 h); no medical intervention/therapy required.
- 1214 • **GRADE 2:** Mild to moderate limitation in activity – some assistance may be needed; no or  
1215 minimal medical intervention/therapy required.
- 1216 • **GRADE 3:** Marked limitation in activity, some assistance usually required; medical  
1217 intervention/therapy required; hospitalization possible.

1218 For each unsolicited AE, an assessment of the relationship of the AE to the study intervention (CHMI/  
1219 antimalarial treatment) was undertaken. Alternative causes of the AE, such as the natural history of pre-  
1220 existing medical conditions, concomitant therapy, other risk factors and the temporal relationship of the  
1221 event to the study intervention were considered. The likely causality of all unsolicited AEs was assessed  
1222 as per the criteria below:

- 1223       • **No Relationship:** No temporal relationship to study intervention **and** alternate aetiology (clinical  
1224       state, environmental or other interventions); **and** does not follow known pattern of response to  
1225       study intervention.
- 1226       • **Unlikely:** Unlikely temporal relationship to study intervention **and** alternate aetiology likely  
1227       (clinical state, environmental or other interventions) **and** does not follow known typical or  
1228       plausible pattern of response to study intervention.
- 1229       • **Possible:** Reasonable temporal relationship to study intervention; **or** event not readily produced  
1230       by clinical state, environmental or other interventions; **or** similar pattern of response to that  
1231       seen with other similar interventions.
- 1232       • **Probable:** Reasonable temporal relationship to study intervention; **and** event not readily  
1233       produced by clinical state, environment, or other interventions **or** known pattern of response  
1234       seen with other similar interventions.
- 1235       • **Definite:** Reasonable temporal relationship to study intervention; **and** event not readily  
1236       produced by clinical state, environment, or other interventions; **and** known pattern of response  
1237       seen with other similar interventions.

1238       AE data also included the results of hematology (full blood count) and biochemistry (liver function tests,  
1239       urea and electrolytes) carried out at dC+9, dC+11, within 12 hours of starting antimalarials after blood  
1240       donation (C+14-14.5), and then at dC+45 and dC+90 (VAC068) and at dC+14, day of diagnosis, T+1, T+6,  
1241       dC+28 and dC+90 (VAC069A).

## 1242       **Gametocyte quantification**

1243       *P. vivax* gametocytemia was determined by one-step quantitative reverse transcription PCR (qRT-PCR)  
1244       targeting the messenger RNA marker of female mature gametocytes, *pvs25*. For RNA extraction samples  
1245       were processed within 4 h of blood sampling: here 50  $\mu$ L whole blood was mixed with 250  $\mu$ L RNA  
1246       protect reagent (Qiagen) for RNA stabilization, until the blood was lysed and had turned black. Samples  
1247       were then stored at -20 °C. Subsequently, 600  $\mu$ L D-PBS with 1 %  $\beta$ -ME was added to each sample and  
1248       then centrifuged for 15 min at 15,000  $xg$ , the supernatant removed and the pellet resuspended in 300  
1249        $\mu$ L RLT lysis buffer (Qiagen) + 1 %  $\beta$ -ME with 20  $\mu$ L proteinase K and incubated at 55°C for 10 min. The  
1250       samples were homogenized into a QIAshredder column (Qiagen) and purified through an RNeasy mini  
1251       spin column (Qiagen) as per the manufacturer's instructions. Each sample was then eluted in 100  $\mu$ L  
1252       RNase-free water. Thereafter, one-step RT-PCR was performed using Luna® Universal Probe One-Step

1253 RT-qPCR Kit (New England Biolabs). Briefly, 5  $\mu$ L RNA extract was added to a final reaction volume of 25  
1254  $\mu$ L consisting of 12.5  $\mu$ L Luna<sup>®</sup> Universal qPCR Master Mix, 0.625  $\mu$ L Pv25 MGB-FAM probe (5'-CCA ATC  
1255 CAG AAG ATG AGA-3'), 1.25  $\mu$ L of each primer (diluted at 10  $\mu$ M), and 3.375  $\mu$ L nuclease-free water and  
1256 1  $\mu$ L reverse transcriptase (RT) enzyme (NEB). The *pvs25* primer sequences were 5'-GTT GCT CAT GTG  
1257 CTA TTG-3' for the forward primer and 5'-CAG ACT TCA TTA TCT GTG TTA-3' for the reverse primer.  
1258 Analyses were performed on a StepOne Plus machine (Thermo Fisher Scientific) using the StepOne  
1259 software v2.3. The thermal conditions consisted of reverse transcription (55 °C for 10 min), enzyme  
1260 activation (95 °C for 1 min) and two-temperature cycling steps (95 °C for 10 s, 60 °C for 1 min, for 45  
1261 cycles). All samples were tested in triplicate. Controls without RT enzyme were added to exclude false  
1262 positives due to the presence of genomic DNA and were tested in duplicate. Ct values were converted  
1263 into *pvs25* transcript/ $\mu$ L using plate-specific standard curves, generated by serial-diluted *pvs25* RNA  
1264 transcripts (10<sup>7</sup> - 10 copies/ $\mu$ L). Final values were multiplied by 2 (dilution factor at the RNA extraction  
1265 step) to report per  $\mu$ L of the original blood sample. *pvs25* RNA transcripts were produced by  
1266 amplification of the *pvs25* gene by T7 polymerase (HiScribe T7 High Yield RNA Synthesis Kit); RNA  
1267 purified by lithium chloride extraction before treatment with DNase I (Qiagen) to eliminate residual  
1268 DNA; standards were diluted in DNA-free H<sub>2</sub>O containing a background of 5 % aspecific human RNA  
1269 (isolated from blood of a healthy donor), to improve linearity of the standard curve.

## 1270 **Modelling of PMR – VAC068**

1271 A qPCR-derived parasite multiplication rate (PMR) was modelled based on previously described  
1272 methodology (28, 53, 70). In brief, to model the PMR, the arithmetic mean of the three replicate qPCR  
1273 results obtained for each individual at each time-point was used for model-fitting. Negative individual  
1274 replicates were assigned a value of 0 gc/mL for the purposes of calculating the arithmetic mean of  
1275 triplicates (where at least one of the three readings was positive). All qPCR data points which, based  
1276 upon the mean of the three replicates, were >5 gc/mL were used for modelling and any values ranging  
1277 from 1-5 gc/mL were replaced with 5 gc/mL. The time interval between the morning and evening bleeds  
1278 used for qPCR monitoring was set as 0.3 days. PMR per 48 hours was then calculated using a linear  
1279 model fitted to log<sub>10</sub>-transformed qPCR data.

## 1280 **Modelling of PMR – VAC069A**

1281 Analysis of VAC069A was performed as for VAC068 but additionally any data point that was negative but  
1282 preceded a positive data point was replaced with a value = 5 gc/mL; otherwise negative data points  
1283 occurring after any positive data point but not preceding a positive data point were treated as 0 gc/mL.  
1284 The time interval between the morning and evening bleeds used for qPCR monitoring in this study was  
1285 set as 0.37 days. PMR per 48 hours was then calculated using a linear model fitted to log<sub>10</sub>-transformed  
1286 qPCR data.

## 1287 **Peripheral blood mononuclear cell (PBMC), plasma and serum preparation**

1288 Blood samples were collected into lithium heparin-treated vacutainer blood collection systems (Becton  
1289 Dickinson, UK). PBMC were frozen in foetal calf serum (FCS) containing 10% dimethyl sulfoxide (DMSO)  
1290 and stored in liquid nitrogen. Plasma samples were stored at -80 °C. For serum preparation, untreated  
1291 blood samples were stored at room temperature (RT) and then the clotted blood was centrifuged for 5  
1292 min (1000 *xg*). Serum was stored at -80 °C.

## 1293 **Anti-PvDBP\_RII standardized ELISA**

1294 ELISAs to quantify circulating PvDBP\_RII-specific total IgG responses were performed using standardized  
1295 methodology, similar to that previously described (29). Day C-1 and dC+90 serum or plasma samples  
1296 from the VAC068 and VAC069A volunteers were tested, alongside samples from 8 healthy UK adults  
1297 previously vaccinated in the VAC051 Phase Ia trial of a candidate PvDBP\_RII vaccine (Group 2C) (29).  
1298 Nunc MaxiSorp ELISA plates (Thermo Fisher) were coated overnight ( $\geq 16$  h) at 4 °C with 50  $\mu$ L per well of  
1299 2  $\mu$ g/mL PvDBP\_RII (Sall allele) protein (29). Plates were washed 6x with 0.05 % PBS/Tween (PBS/T) and  
1300 tapped dry. Plates were blocked for 1 h with 100  $\mu$ L per well of Starting Block™ T20 (Thermo Fisher) at  
1301 20 °C. Test samples were diluted in blocking buffer (minimum dilution of 1:100), and 50  $\mu$ L per well was  
1302 added to the plate in triplicate. Reference serum (made from a pool of high-titer vaccinated donor  
1303 serum) was diluted in blocking buffer in a three-fold dilution series to form a ten-point standard curve.  
1304 Three independent dilutions of the reference serum were made to serve as internal controls. The  
1305 standard curve and internal controls were added to the plate at 50  $\mu$ L per well in duplicate. Plates were  
1306 incubated for 2 h at 20 °C and then washed 6x with PBS/T and tapped dry. Goat anti-human IgG–alkaline  
1307 phosphatase secondary antibody (Merck) was diluted 1:1000 in blocking buffer and 50  $\mu$ L per well was

1308 added. Plates were incubated for 1 h at 20 °C. Plates were washed 6x with PBS/T and tapped dry. 100 µL  
1309 per well of PNPP alkaline phosphatase substrate (Thermo Fisher) was added, and plates were incubated  
1310 for approximately 15 min at 20 °C. Optical density at 405 nm (OD<sub>405</sub>) was measured using an ELx808  
1311 absorbance reader (BioTek) until the internal control reached an OD<sub>405</sub> of 1.0. The reciprocal of the  
1312 internal control dilution giving an OD<sub>405</sub> of 1.0 was used to assign an arbitrary unit (AU) value of the  
1313 standard. Gen5 ELISA software v3.04 (BioTek) was used to convert the OD<sub>405</sub> of test samples into AU by  
1314 interpolating from the linear range of the standard curve fitted to a four-parameter logistic model. Any  
1315 test samples with an OD<sub>405</sub> below the linear range of the standard curve at the minimum dilution tested  
1316 were assigned a minimum AU value of 5.0.

### 1317 **Anti-PvMSP1<sub>19</sub> ELISA**

1318 Anti-PvMSP1<sub>19</sub>-specific total IgG responses were measured in VAC068 and VAC069A volunteer serum  
1319 and plasma via indirect ELISA (same test samples as for the PvDBP\_RII ELISA). Nunc MaxiSorp ELISA  
1320 plates (Thermo Fisher) were coated with 50 µL per well of 2 µg/mL PvMSP1<sub>19</sub> protein (kindly provided by  
1321 Dr Chetan Chitnis (71)) and left overnight (≥16 h) at 4 °C. Plates were washed 6x with 0.05% PBS/T and  
1322 tapped dry. Plates were blocked for 1 h with 100 µL per well Starting Block™ T20 (Thermo Fisher) at  
1323 20 °C. Test samples were diluted 1:100 in blocking buffer and 50 µL per well was added in duplicate. A  
1324 1:6400 dilution of a post-CHMI positive control serum sample was also added in duplicate. Plates were  
1325 incubated for 2 h at 20 °C and then washed 6x with PBS/T and tapped dry. Goat anti-human IgG–alkaline  
1326 phosphatase secondary antibody (Merck) was diluted 1:1000 in blocking buffer and 50 µL per well was  
1327 added. Plates were incubated for 1 h at 20 °C, then washed 6x with PBS/T and tapped dry. 100 µL per  
1328 well of PNPP alkaline phosphatase substrate (Thermo Fisher) was added and plates were incubated for  
1329 approximately 20 min at 20 °C. OD<sub>405</sub> was measured using an ELx808 absorbance reader (BioTek) until  
1330 the positive control reach an OD<sub>405</sub> of 1.0. Results are plotted as the mean OD<sub>405</sub> reading for each test  
1331 sample.

### 1332 **Illumina sequencing**

1333 Blood samples were used from the two volunteers in VAC068 as follows: first volunteer = 1 x 10 mL  
1334 packed RBC (dC+11), plus 1 x 1.5 mL + 1 x 2 mL packed RBC (dC+14); second volunteer = 1 x 10 mL  
1335 packed RBC (dC+11), plus 2 x 2.5 mL packed RBC (dC+14). DNA was extracted using the Qiagen blood  
1336 DNA midi kit and sequenced with Illumina HiSeq X10 with 150 bp paired end reads.

1337 **Long read sequencing**

1338 Preparation of schizonts: For the preparation of high molecular weight DNA for long-read sequencing  
1339 blood samples were collected at diagnosis from volunteers enrolled in VAC069A and used to culture  
1340 schizonts *ex vivo*. This approach was chosen to maximize the quantity of parasite DNA available. Briefly,  
1341 20 mL whole blood was depleted of leukocytes using NWF filters. RBC were then washed in McCoy's  
1342 medium and resuspended at 3 % hematocrit. Parasite growth medium (McCoy's) was supplemented  
1343 with 20 % AB human serum, 2.4 mg/mL D-glucose, 25 mM HEPES, 0.2 mM hypoxanthine and flasks were  
1344 gassed with 5% O<sub>2</sub>, 5% CO<sub>2</sub> (in N<sub>2</sub>) and incubated at 37 °C. The duration of culture was adapted to allow  
1345 schizont maturation, based on the dominant life cycle stage present at the start of culture, as  
1346 determined by Giemsa-stained thin and thick blood smears. Twelve hours prior to end of culture, the  
1347 protease inhibitor E64 was added at a final concentration of 10 µM to prevent schizont rupture. At the  
1348 end of the culture red cells were lysed and parasites isolated according to our previously published  
1349 protocol: <https://dx.doi.org/10.17504/protocols.io.brgjm3un>. In brief, RBC were washed in PBS and  
1350 lysed in 0.0075 % saponin for 10-15 min on ice; samples were then centrifuged at 2000 xg to pellet  
1351 schizonts, which were snap-frozen on dry ice; and the supernatant was centrifuged at 18,000 xg to  
1352 pellet less mature parasites (rings and trophozoites) – these were also snap frozen on dry ice. In the  
1353 following steps for DNA extraction, samples containing different parasite stages were pooled to  
1354 maximize the yield, and samples from all volunteers (except 01-003) were taken forward for sequencing.

1355 High molecular weight DNA extraction: PvW1 parasite pellets were pooled into four groups. Each group  
1356 was thawed on ice, resuspended in 200 µL cold PBS and extracted using the Qiagen MagAttract® HMW  
1357 DNA Kit (blood protocol). This yielded a total of 107 ng high molecular weight DNA with an average  
1358 fragment size of 78 kbp as measured by Femto Pulse system (Agilent).

1359 Shearing and PacBio library construction and sequencing: The pooled high molecular weight DNA (107  
1360 ng) was sheared using a Diagenode Megaruptor 3 (speed setting 30) to an average fragment size of 18.2  
1361 kbp. SMRTbell® library preparation and clean up were as described in the manufacturer's protocol for  
1362 low input DNA: [https://www.pacb.com/wp-content/uploads/Procedure-Checklist-Preparing-HiFi-](https://www.pacb.com/wp-content/uploads/Procedure-Checklist-Preparing-HiFi-Libraries-from-Low-DNA-Input-Using-SMRTbell-Express-Template-Prep-Kit-2.0.pdf)  
1363 [Libraries-from-Low-DNA-Input-Using-SMRTbell-Express-Template-Prep-Kit-2.0.pdf](https://www.pacb.com/wp-content/uploads/Procedure-Checklist-Preparing-HiFi-Libraries-from-Low-DNA-Input-Using-SMRTbell-Express-Template-Prep-Kit-2.0.pdf). After a 1.8x Ampure  
1364 PB bead clean-up to remove fragments below 250 bp, 87 ng PvW1 DNA remained for library  
1365 preparation, which produced 30 ng of SMRTbell® library for sequencing. The SMRT libraries were  
1366 sequenced on a single Sequel SMRT Cell 1M and yielded 13 Gb sequence (3.4 Gb unique).

1367 **Raw sequencing data**

1368 Data are included in the study entitled “PvW1 – a new clone of *Plasmodium vivax* with high quality  
1369 genome assembly ID 6525”; accession number ERP129582.

1370 Illumina:

1371 4472STDY76983 13=1a - ERS6867716

1372 4472STDY76983 14=1b - ERS6867717

1373 4472STDY76983 15=2a - ERS6867718

1374 4472STDY76983 16=2b - ERS6867719

1375 Pacbio:

1376 DN599117N-A1 or 5987STDY8548200 - ERS3947829

1377 **Genome assembly and annotation**

1378 PvW1 genomic assembly and annotation data can be found at:

1379 [ftp://ngs.sanger.ac.uk/scratch/project/pathogens/ea10/pvivax/renamed\\_scaffolds/](ftp://ngs.sanger.ac.uk/scratch/project/pathogens/ea10/pvivax/renamed_scaffolds/)

1380 PacBio subreads from sample DN599117N-A1 (5987STDY8548200) were used for the assembly. Circular  
1381 consensus sequencing reads (CCS) were generated from the subreads using PacBio SMRTLink  
1382 (<https://www.pacb.com/support/software-downloads/>).

1383 Illumina reads: Samples 4472STDY7698313 (volunteer 1a), 4472STDY7698314 (volunteer 1b) and  
1384 4472STDY7698315 (volunteer 2a) from STDY4472 were used for assembly polishing. The Illumina reads  
1385 were processed with CutAdapt 2.7 (72) to remove adapter sequences.

1386 Decontamination of the sequencing data: To identify contaminant species in the sequencing data, BLAST  
1387 searches of a randomly selected subset of subread sequences were run against the NCBI nt and nr  
1388 databases (February 2020 versions) (73). The list of detected contaminants was then extended using  
1389 Diamond 0.9.22 (74) BLASTX of the PacBio subreads and CCS reads against a database that contained



1390 39,920 apicomplexan protein sequences and 190,075 protein sequences from various bacterial and  
1391 fungal species. Further classification of sequences by species was performed using BLAST of the CCS  
1392 reads and subreads against a nucleotide database containing the *P. vivax* P01 reference genome (30)  
1393 (PlasmoDB release 46), GRCh38.p13 human genome assembly and 225 bacterial or fungal sequences. In  
1394 parallel with this, the same reference nucleotide sequences were also used for competitive mapping of  
1395 the PacBio and Illumina reads with Minimap2 2.17-r941 (75). Next, a Kraken 2.0.8-beta (76) database  
1396 was made that contained multiple reference genomes of *Plasmodium*, as well as the genomes of human  
1397 and other contaminant species that were detected in the previous steps. This database was used to  
1398 classify the PacBio subreads, CCS reads and Illumina reads. If a PacBio subread was unambiguously  
1399 detected as belonging to a contaminant species, other subreads that had been produced from the same  
1400 zero-mode waveguide (ZMW) were also flagged as contaminants. Information from different  
1401 contaminant detection methods was combined. BLAST against the NCBI nt database (October 2019  
1402 version) was run with the PacBio sequences that still remained unclassified after the previous steps.  
1403 Illumina reads that remained unclassified after running Kraken were removed from the dataset.

1404 In order to verify the effectiveness of Illumina read set decontamination, the Illumina reads were  
1405 assembled with LightAssembler (initial public release version) (77), and the resulting assembly was  
1406 checked for contaminants using Diamond BLASTX. The database for Diamond was the same as previously  
1407 described for the decontamination of PacBio subreads. No contaminant sequences were detected in the  
1408 Illumina assembly.

1409 Canu assembly of PacBio data: Palindromic CCS were detected using a script from PacBio's GitHub  
1410 repository ([https://github.com/PacificBiosciences/apps-  
1411 scripts/blob/master/miscUTILS/missing\\_adaptors.py](https://github.com/PacificBiosciences/apps-scripts/blob/master/miscUTILS/missing_adaptors.py)). The palindromic CCS were removed from the  
1412 dataset. Next, the decontaminated PacBio subreads and CCS were pooled and assembled with Canu  
1413 assembler (78) (with default settings of the pacbio-raw mode, and with the genomeSize=29052596 flag).  
1414 The resulting assembly was deduplicated by merging contigs with unique overlaps using GAP5 v1.2.14-  
1415 r3753M (79). The assembly was polished using the Arrow algorithm in PacBio gcpp (version 1,  
1416 <https://github.com/PacificBiosciences/gcpp>), followed by three iterations of Pilon 1.23 (80).  
1417 Decontaminated Illumina reads (pooled from three samples) were used as the input for Pilon. The  
1418 apicoplast and mitochondrion sequences were circularized using Circlator minimus2 (81). Assembly  
1419 completeness was assessed using BUSCO 3.0.1 (82). The assembly was annotated using the Glasgow

1420 server of Companion (83) (<http://protozoacompanion.gla.ac.uk/>, February 2020 version). The alignment  
1421 of proteins to the reference genome was enabled in the Companion run and the rest of the settings were  
1422 left as default.

1423 Mapping of Illumina reads to estimate the coverage of specific genes: Pooled Illumina reads from three  
1424 samples that had been processed with CutAdapt and decontaminated with Kraken were mapped to the  
1425 assembly with Minimap2 using the short read mapping mode (“-ax sr”).

#### 1426 **VIR gene analysis**

1427 Analysis of the diversity and relatedness amongst the VIR genes of PvW1 compared to PvP01, PvT01,  
1428 PvC01 and Sal-1 was carried out as described in (30).

#### 1429 **Statistical analysis**

1430 Unless otherwise stated, data were analyzed using GraphPad Prism version 9.1.1 for Windows  
1431 (GraphPad Software Inc.). All tests used were 2-tailed and are described in the text. A value of  $P < 0.05$   
1432 was considered significant.